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Pregnancy loss, the demise of a pregnancy at any time between implantation and delivery, is a 
common event in women’s lives, affecting approximately one in three pregnancies. Pregnancy 
loss often causes profound psychological distress to women, their partners, and their families. 
However, despite its frequency and troubling nature, relatively little is known about the natural 
history of pregnancy loss, especially the multitude of signs and symptoms that precede a loss and 
distinguish it from an ongoing healthy pregnancy. One of the challenges in describing the natural 
history of pregnancy loss is that most losses occur very early, before entry to clinical care, 
necessitating the use of preconception cohort studies. Few such studies have ever been conducted 
worldwide. This dissertation aimed to describe the natural history of early pregnancy loss at <20 
weeks gestation for the first time using a unique preconception cohort with daily prospective 
follow-up from the start of the pregnancy attempt through seven weeks post-conception.   
 
To accomplish this goal, three specific aims were undertaken. First, a systematic literature 
review was conducted to synthesize the existing literature on the relationships between the signs 
and symptoms and pregnancy loss. Two analytic aims were then undertaken to delineate 
thoroughly the relationships between prospectively ascertained signs and symptoms—namely, 
vaginal bleeding, lower abdominal cramping, nausea and vomiting (hereafter referred to as 
 
 
“signs and symptoms”)—and subsequent early pregnancy loss. The first analytic aim used a 
fixed covariate and fixed effect survival analytic approach to estimate the cumulative incidence 
of early pregnancy loss by the presence of individual, combinations, and patterns of signs and 
symptoms and the associations between signs and symptoms and the cumulative incidence of 
pregnancy loss. The second analytic aim used a time-varying covariate and time-varying effect 
survival analytic approach to estimate the weekly associations between signs and symptoms and 
pregnancy loss to determine if these relationships were consistent or divergent across gestational 
ages. The results of the first and second analytic aims were then compared to gain a more 
complete understanding of the natural history of early pregnancy loss. 
 
The literature review revealed a dearth of studies on the signs and symptoms of pregnancy loss. 
Two preconception and 16 pregnancy cohort studies were identified. The literature suggested 
that vaginal bleeding, particularly heavy vaginal bleeding, was associated with an increased risk 
of pregnancy loss while vomiting, and in some studies nausea, was associated with a decreased 
risk of pregnancy loss. However, reliance on care-seeking cohorts, maternal retrospective reports 
of signs and symptoms after pregnancy loss, and retrospective recall of signs and symptoms over 
long periods (e.g., entire trimesters) may have biased the observed associations between signs 
and symptoms and pregnancy loss leading to incorrect inferences regarding the relationships 
between signs and symptoms and pregnancy loss.  
 
The two analytic aims addressed the data gaps identified in the literature review. The 
preconception cohort design with prospective daily follow-up from the beginning of the 
 
 
pregnancy attempt facilitated the ascertainment of pregnancies at the earliest stages of gestation 
and losses prior to clinical care entry through the use of urine-based home pregnancy testing. The 
daily reporting of multiple signs and symptoms in the first five weeks after a positive home 
pregnancy test, or approximately two to seven weeks post-conception, allowed for a full 
description of the relationships between signs and symptoms of pregnancy loss without recall 
bias.  
 
Data for the two analytic aims come from the Longitudinal Investigation of Fertility and the 
Environment (LIFE) Study, a population-based cohort with preconception recruitment of couples 
in 16 counties in Michigan and Texas followed for 12 months of trying for pregnancy and then 
through pregnancy loss or delivery for couples achieving an hCG pregnancy. 501 couples 
entered the study, and 347 achieved a pregnancy during the study period. Three hundred forty-
one singleton pregnancies comprise the study population for the two analytic aims in this 
dissertation. Overall, 95 (28%) pregnancies in the study population ended in a pregnancy loss. 
Lower abdominal cramping, nausea, and vomiting were often reported during the early 
pregnancy period; vaginal bleeding was less common. The results of the fixed covariate fixed 
effect survival analysis from the first analytic aim demonstrated that vaginal bleeding, 
particularly heavy bleeding and bleeding accompanied by lower abdominal cramping, was 
associated with an increased risk of pregnancy loss. In contrast, the presence of vomiting, but not 
nausea alone, during the early pregnancy period was associated with a lower risk of loss. 
Analyses in the second analytic aim using weekly time-varying covariates and time-varying 
effects of signs and symptoms on pregnancy loss revealed some new findings. The first week 
after a positive pregnancy test appeared to be a vulnerable period. Vaginal bleeding and lower 
 
 
abdominal cramping were associated with an increased risk of loss in the first week but not in 
later weeks; conversely, nausea and/or vomiting were associated with lower risk of pregnancy 
loss but only after the first week.  
 
The observed weekly variations in the signs and symptoms of pregnancy loss may reflect 
changes in maternal adaptation to pregnancy across gestation. Overall, relatively little is known 
about the biological processes underlying healthy and unhealthy adaption to pregnancy as well as 
how embryo quality may affect these adaptive processes. More work is required from basic 
scientists, clinicians and epidemiologists to better understand the causes of signs and symptoms 
and their relationships to pregnancy loss, including genetic and environmental factors and their 
interactions. In the meantime, prognostic models developed from data in this dissertation using 
time-varying signs and symptoms may be useful to women and their health care providers for 
identifying pregnancies at increased risk for pregnancy loss. These models could prompt women 
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When you find yourselves in darkness, may you also find a light to guide you out; 
 
To future generations of women, 
May the efforts of those of us on Earth today  
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You have led me out of the darkness countless times,  
Thank you, 
Main tumse pyaar karti hoon.
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CHAPTER 1: INTRODUCTION 
 
Pregnancy loss, from implantation through delivery, is a common, often upsetting, and poorly 
understood event in women’s lives. Estimates of the cumulative incidence of pregnancy loss 
from prospective preconception studies vary widely, though many studies report one loss in 
every three to four pregnancies.1-21 Most losses occur very early in pregnancy, prior to clinical 
care entry, and are often only detected by sensitive tests for human chorionic gonadotropin 
(hCG).1,2,4,8,9,13,14,16,18,19,22 Despite the frequency of pregnancy loss, its natural history, and the 
temporal ordering of multiple signs and symptoms in relation to loss, has yet to be fully 
delineated.  Data from prospective preconception cohort studies are necessary in order to assess 
the relationship between specific signs and symptoms and early pregnancy loss. However, such 
data are limited due to the cost and complexity of implementing preconception cohort studies. 
The goal of the literature review was to identify and summarize the existing literature to provide 
the context and motivation for the two analytic aims.  
 
Specific Aim 1. To conduct a comprehensive literature review on the associations between signs 
and symptoms and pregnancy loss. Due to the dearth of literature on the signs and symptoms 
associated with pregnancy loss, I included findings from preconception and prospective 
pregnancy cohort studies. This review summarized the existing literature, highlighting the 
critical data gaps in the natural history of pregnancy loss, and included some discussion on the 
putative mechanisms by which signs and symptoms may precede a pregnancy loss. This review 




In the context of limited prospective data on signs and symptoms of pregnancy loss, the 
overarching goal of the two analytic aims of this dissertation was to describe the natural history 
of pregnancy loss <20 weeks gestation by delineating the temporal ordering of signs and 
symptoms during 4-9 weeks gestation in relation to early pregnancy loss using data from the 
Longitudinal Investigation of Fertility and the Environment (LIFE) Study, a prospective 
preconception, population-based cohort of 501 couples attempting pregnancy in Michigan and 
Texas, USA. To my knowledge, the LIFE Study was the first to collect daily data on multiple 
signs and symptoms during the early pregnancy period.  
 
The two analytic approaches for Aims 2 and 3 were chosen because they addressed different, but 
complimentary, questions using available data from the LIFE Study. Using a fixed covariate, 
fixed effect approach in Aim 2, I answered the question about the average effect (i.e., marginal 
means) of individual and combinations of signs and symptoms occurring from ~4-9 weeks 
gestation on early pregnancy loss. Using a time-varying covariate, time-varying effect approach 
in Aim 3, I answered the question about the week-specific effects of individual and combinations 
of signs and symptoms occurring from ~4-9 weeks gestation on early pregnancy loss and 
whether these relationships change across gestation. Taken together, the results from these two 
aims provided information about average and week-specific effects of signs and symptoms on 
early pregnancy loss. They also provided information on the effects of shorter (weekly) and 




Specific Aim 2. To delineate the natural history of pregnancy loss as captured by the daily 
reporting of possible signs and symptoms of loss from two to seven weeks post-conception. The 
incidence of signs and symptoms among women experiencing pregnancy loss was described and 
contrasted with the incidence among women not experiencing a loss.  Pregnancy loss included 
losses <20 weeks gestation, exclusive of ectopic pregnancies. Signs and symptoms were included 
as fixed covariates with fixed effects on pregnancy loss across gestational age in survival 
analytic models. Signs and symptoms included bleeding, lower abdominal cramping, and nausea 
and/or vomiting. Individual signs and symptoms, combinations of signs and symptoms, and 
temporal patterning of signs and symptoms in relation to pregnancy loss were evaluated. 
 
Specific Aim 3. To determine whether the associations between signs and symptoms and 
pregnancy loss were modified by gestational age at loss. Survival models similar to those in Aim 
2 were constructed with two important differences: the signs and symptoms and the effects of 
signs and symptoms were allowed to vary across gestational ages. By allowing the associations 
between signs and symptoms and pregnancy loss to vary, I was able to determine if the 
relationships between signs and symptoms and pregnancy loss were modified by gestational age. 
Results from the time-varying effect survival models were compared with the results from the 










Approximately one-third of pregnancies end in a loss; however, the natural history of early 
pregnancy loss, including signs and symptoms preceding a loss, has yet to be fully described. I 
searched PubMed/MEDLINE and Embase to identify articles with prospective ascertainment of 
signs and symptoms of pregnancy loss <20 weeks gestation in spontaneous conceptions with a 
focus on vaginal bleeding, nausea, and vomiting. Two preconception and 16 pregnancy cohort 
studies that attempted to ascertain information on bleeding and/or nausea/vomiting prior to the 
ascertainment of pregnancy loss were included. Data from these studies indicated that vaginal 
bleeding was associated with an increased risk of loss, while nausea and vomiting were 
associated with a decreased risk of loss, though these studies were mostly comprised of 
pregnancies surviving into the late first trimester. While such associations were biologically 
plausible, these study designs were subject to bias given recruitment of women at later 
gestational ages and reliance on women presenting to care and reporting symptoms to their 
clinicians. Furthermore, the details of reporting across studies varied greatly with only one study 
collecting daily data on bleeding. Unstructured reporting (e.g., unprompted reporting to 
clinicians) or reporting over long periods (e.g., monthly) may have introduced reporting error 
and bias. Data gaps remain regarding 1) relationships between signs and symptoms and losses 
occurring very early, prior to care entry, 2) patterns of the different signs and symptoms 
preceding pregnancy loss, and 3) empirical testing of whether relationships between signs and 





Pregnancy loss is the spontaneous end of a pregnancy resulting in embryonic or fetal demise at 
any point from implantation through delivery. Pregnancy loss affects approximately one-third of 
pregnancies and most often occurs before viability during the first and early second trimesters.4,14 
Pregnancy loss is often an upsetting event for both women and their partners.23-28 Despite the 
frequency and potentially distressing nature of pregnancy loss, the pathophysiology of such loss 
remains poorly understood, and its natural history, including temporal ordering of signs 
(objective findings by clinician or patient) and symptoms (subjective patient experience) in early 
pregnancy has yet to be fully described.  
 
The signs and symptoms of pregnancy and loss most often evaluated in epidemiologic studies 
include nausea, vomiting, and vaginal bleeding with or without associated pain and/or cramping. 
Nausea and vomiting are believed to be protective against pregnancy loss while bleeding, pain, 
and cramping are believed to be more ominous. Given the need to more thoroughly delineate the 
signs and symptoms of pregnancy loss, the objectives of this review were 1) to determine the 
state of existing knowledge on signs and symptoms of early pregnancy loss (<20 weeks 
gestation) with regards to the incidence of signs and symptoms and the cumulative incidence of 
early pregnancy loss in women with and without signs and symptoms and 2) to identify any data 









I conducted a PubMed/MEDLINE search using search parameters listed in Table 2.1.A. Searches 
for abortion, spontaneous (MeSH Term) and miscarriage (MeSH Term) yielded the same results. 
I also conducted an Embase search using search parameters listed in Table 2.1.B. Reference lists 
of all included papers were also crosschecked, and the reference lists of prior review papers on 
bleeding29,30 or nausea and/or vomiting of pregnancy (NVP)31,32 were searched. No restrictions 
were placed on publication date. Only articles written in English were included. I completed all 




Preconception studies are ideal for evaluating the relationships between signs and symptoms and 
early pregnancy loss as they can capture all pregnancies detectable by available technology (e.g., 
highly sensitive home pregnancy tests), and they do not depend upon pregnancies surviving until 
clinical detection. However, due to a dearth of preconception studies on signs and symptoms 
associated with pregnancy loss, I also included prospective cohort studies recruiting women 
during pregnancy. I excluded studies focused on couples seeking infertility treatment, women 
with recurrent pregnancy loss, ectopic pregnancy, molar pregnancy, twin pregnancy, antepartum 
hemorrhage, subchorionic hematoma, hyperemesis gravidarum or existing medical conditions, 
studies with report of symptoms exclusively after pregnancy loss (including case-control 
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studies), studies where prescription of antiemetic drugs was used as proxy for vomiting, studies 
where indication for ultrasound or chief complaint for emergency department presentation were 
used as proxies for bleeding, studies without a comparison group or an inappropriate comparison 
group (e.g., ectopic pregnancies), studies focused on prediction of viability using ultrasound or 
biological markers, studies on treatments for nausea and vomiting, studies on stillbirth, preterm 
birth or other adverse pregnancy outcomes, and studies without data on pregnancy outcomes. 
Studies on threatened abortion were only included if they compared loss rates in women with 
and without other signs and symptoms (e.g., nausea and/or vomiting). Matched cohort study 
designs were excluded as incidence of signs and symptoms could not be estimated. Cross-
sectional studies were excluded since the outcomes for all pregnancies were not known at the 
time of the study’s end. Abstracts were read to ensure articles met the inclusion/exclusion 





Given the paucity of data from preconception studies, my synthesis considered both 
preconception and pregnancy cohort studies together despite selection and reporting biases 
inherent in this design (discussed in the Limitations of existing literature on signs and symptoms 
of pregnancy loss subsection below). The cumulative incidence of each sign and symptom as 
well as the cumulative incidence of pregnancy loss among women experiencing and not 
experiencing specific signs and symptoms were reported. Risk of pregnancy loss in women with 
signs and symptoms was compared with risk of loss in women without signs and symptoms 
8 
 
using data abstracted from the articles to estimate risk ratios (RR) and 95% confidence intervals 




Figure 2.1 shows the number of articles identified, excluded, and included in the final review. 
The literature search yielded 19,550 articles of which 4,187 were duplicates leaving 16,804 
unique titles. 112 articles passed the title review and their abstracts were read. 45 articles passed 
the abstract review and the full-text was read for suitability of inclusion in the review. Of these 
articles, 29 were excluded for the following reasons: indication for ultrasound proxy (n=6), chief 
complaint proxy (n=3), no comparison group (n=5), inappropriate comparison group (n=3),  
other pregnancy outcome (n=4), antepartum hemorrhage (n=1), other signs or symptoms (n=1), 
retrospective report (n=1), biomarker prediction study (n=2), matched cohort study (n=1), and 
cross-sectional study (n=2). Two additional studies were identified from previous systematic 
reviews and reference lists of included articles. In total, 18 studies were included in the review 
on the incidence of signs and symptoms and associations with pregnancy loss <20 weeks 
gestation. Two studies were preconception cohorts, and 16 studies were pregnancy cohorts. 
 




Four prospective studies on vaginal bleeding and its association with pregnancy loss from 
cohorts of women seeking prenatal care were included (Table 2.2).33-36 The studies were 
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conducted from the 1960s into the 2000s in three different countries, and sample sizes ranged 
from 550 patients in a general practice to >16,000 patients in a multicenter trial for trisomy 21 
screening. The incidence of vaginal bleeding in pregnancy ranged from 7-21%, with the wide 
range likely reflecting the varying extent to which bleeding was captured in medical charts, 
which depended upon (1) gestational age at care-seeking, (2) women reporting bleeding, and (3) 
clinicians recording the reports. The incidence of loss in women with bleeding ranged from 1-
56%, while the incidence of loss among women without bleeding ranged from <1-7% of women. 
This resulted in RRs of 2.6 (95% CI: 1.3, 5.2),33 2.8 (95% CI: 1.7, 4.4),36 8.6 (95% CI: 6.6, 
11.2),35 and 120 (95% CI: 30, 484)34 in the four studies. In one study reporting on severity of 
bleeding, heavy bleeding carried a greater risk of loss relative to no bleeding (RR 4.9, 95% CI: 




Two prospective cohort studies of female volunteers recruited from the community were 
included (Table 2.2).37,38 In one US preconception cohort of 151 pregnancies, the cumulative 
incidence of bleeding ≤8 weeks gestational age among pregnancies surviving ≥6 weeks 
gestational age was 9%.38 Only 15 pregnancy losses were recorded, with 2 occurring among 14 
women with bleeding (14%) and 13 occurring among 137 women without bleeding (9%), 
yielding an RR of 1.5 (95% CI: 0.4, 6.0) for bleeding. In a US pregnancy cohort of 4,510 
pregnancies, the cumulative incidence of retrospectively reported first trimester bleeding was 
27% with 8% reporting heavy bleeding.37 Cumulative incidence of loss was 11% in women with 
any bleeding, 24% in women with heavy bleeding, and 12% in women without any bleeding. 
10 
 
Any bleeding versus no bleeding was not associated with pregnancy loss (RR 0.9, 95% CI: 0.8, 
1.1); however, heavy bleeding was associated with increased risk of pregnancy loss (RR 2.0, 
95% CI: 1.4, 3.0); heavy bleeding accompanied by pain was associated with the highest risk of 
loss (RR 3.1, 95% CI: 2.1, 4.5). Longer duration of bleeding was also noted to increase the risk 
of pregnancy loss. Though not statistically evaluated, it was also observed that the weekly 
probability of loss among women with bleeding was greater earlier in gestation.   
 




Nine prospective studies of NVP and its associations with pregnancy loss among cohorts of 
women seeking prenatal care were included,39-47 spanning four countries and 50 years (four had 
sample sizes >1000 patients, Table 2.3). These included studies from a large insurance 
provider,39,46 the multicenter Collaborative Perinatal Project,40 and a study of women seeking 
prenatal care in Malmo, Sweden.47 Incidence of NVP prior to 20 weeks gestation ranged from 
65-89%. Incidence of loss among women with NVP (range 0-11%) was lower than the incidence 
of loss among women without NVP (range 7-35%), resulting in RRs ranging from 0.2-0.6. 
 
Several studies have reported the cumulative incidence of vomiting separately.40,43-45 The 
incidence of vomiting ranged from 46-56%. The cumulative incidence of loss was consistently 
lower among women with vomiting (range 1-5%) than among women with nausea alone (range 
11 
 
4-10%). The RRs for vomiting compared with no NVP ranged from 0.1-0.6 whereas the RRs for 




Two prospective studies on NVP and its associations with pregnancy loss among cohorts of 
female volunteers recruited from the community were included (Table 2.3).48,49 One was a US 
preconception study of 585 pregnancies with monthly reporting of nausea allowing for reporting 
after a loss.49 Eighty-eight percent of women reported first trimester nausea; 7% of women with 
nausea had a loss compared with 30% in women without first trimester nausea (RR 0.2, 95% CI: 
0.2, 0.4). In a US pregnancy cohort of 2,407 pregnancies with first trimester recruitment, 89% 
reported NVP in first or second trimesters; 53% reported vomiting.48 Odds of loss were greater in 
women without NVP compared with any NVP (odds ratio 5.7, 95% CI: 4.0, 8.0). Odds of loss 
were also greater in women with nausea only compared with vomiting (odds ratio 2.4, 95% CI: 
1.8, 3.3).  
 
Patterning of signs and symptoms of pregnancy loss  
 
Evidence from clinical reports in the 1950s suggested some combinations of signs and symptoms 
may portend pregnancy loss. Speert and Guttmacher42 noted that among 31 patients with a first 
trimester loss, three-quarters had no NVP whereas among 225 women who did not experience 
loss, including 49 who reported bleeding, 70% reported some NVP. They concluded that heavier, 
darker bleeding accompanied by cramping in the absence of nausea likely signaled impending 
12 
 
loss. Medalie41 also noted the protective association of NVP against loss in the setting of 
bleeding. Among 23 women with bleeding, one woman reported moderate/severe NVP and she 
did not experience a loss while 50% of women reporting no/mild NVP did experience loss 
(Table 2.4). More recently, among a series of women presenting for threatened abortion between 
5-10 weeks gestation who were followed through 16 weeks gestational age, women who reported 
nausea during pregnancy were less likely to experience loss than women without nausea (hazard 






Data from prospective studies, mostly conducted among care-seeking populations recruited 
during pregnancy, suggested that vaginal bleeding was associated with increased risk of 
pregnancy loss, while nausea and vomiting were inversely associated with pregnancy loss. 
However, there were several potential biases inherent in these study designs, namely, length-
biased sampling (selective inclusion of late pregnancy losses, see Limitations of existing 
literature on signs and symptoms of pregnancy loss subsection below), recall bias (reporting of 
signs and symptoms after a loss), and under-ascertainment of signs and symptoms (signs and 
symptoms not completely captured in medical charts). Such biases may have affected the validity 
of these results.51,52 Furthermore, the details of reporting across studies varied greatly with only 
one study collecting daily data on bleeding. Unstructured reporting (e.g., unprompted reporting 
to clinicians) or reporting over long periods (e.g., monthly) also may have introduced reporting 
error, and could have decreased the precision of the estimates. Caution is particularly warranted 
13 
 
in generalizing findings to losses occurring prior to care entry, which constituted the majority of 
losses.4,53 Despite the biases inherent in these studies, the observed associations are biologically 
plausible. 
 
Physiology of bleeding in relation to pregnancy outcomes 
 
Bleeding may be a cause and/or consequence of pregnancy loss. Women who experience either a 
complete or incomplete abortion must also experience vaginal bleeding by clinical definition.54 
In these cases, bleeding is a consequence of a loss, as this bleeding occurs concurrently with the 
expulsion of the products of conception from the uterus. Not all women, however, experience 
bleeding prior to recognition of the pregnancy loss. This is the case in women experiencing a 
missed abortion.  
 
Subchorionic hemorrhage, which is bleeding between the uterine wall and the chorion detected 
by ultrasonography, is often, though not always, associated with vaginal bleeding and has been 
described as a cause of pregnancy loss.55 Mechanisms have been proposed to explain the 
consequence of pregnancy loss resulting from bleeding during pregnancy. Johns and colleagues56 
have suggested that bleeding early in pregnancy causes increased oxygenation of the embryonic 
environment, which interferes with embryonic and placental development resulting in pregnancy 
loss. Under this hypothesis, oxygenation beyond what is chemically required during early 
gestation results in the formation of reactive oxygen species (ROS) that interfere with 
trophoblastic cells during a period of rapid cell division that is particularly sensitive to insults 
from ROS. Subchorionic bleeding during pregnancy is believed to be one pathway by which the 
14 
 
oxygen-rich maternal blood supply prematurely perfuses the intervillous space.56 Chronic 
inflammatory processes associated with subchorionic bleeding/hematoma may also lead to 
myometrial contractions and expulsion of the gestational sac.56  
 
Physiology of nausea and vomiting in relation to pregnancy outcomes 
 
Two hypotheses promote NVP as the cause of healthy pregnancies: the “maternal-embryo 
protection hypothesis” advanced by Hook,57 Profet,58 and Sherman and Flaxman59 and the 
“growth generating hypothesis” proposed by Huxley.60 Under the maternal-embryo protection 
hypothesis, NVP functions to reduce consumption of potentially harmful foods (e.g., plants with 
phytotoxins or meats contaminated with parasites or pathogens) during the period of 
organogenesis to prevent congenital malformations or pregnancy loss.61 Indeed, women report 
aversions to meat, alcohol, and caffeine during early pregnancy with an increased preference for 
carbohydrate-rich foods.61 Under the growth generating hypothesis, caloric energy restriction 
secondary to NVP in the first trimester stimulates placental growth, which is necessary to 
successfully maintain pregnancy. In response to reduced caloric intake, maternal levels of insulin 
and insulin growth factor-1 (IGF-1) fall. This in turn inhibits maternal anabolic processes and 
redistributes nutrient partitioning to favor placental development.60  
 
An alternative hypothesis suggests that NVP is a consequence of an already well-developing 
pregnancy.62,63 As low hCG levels can be associated with both failing pregnancy and an absence 
of NVP, NVP may merely be an indicator of the embryo quality or viability,62 resulting in 
reverse causation. This theory attributing NVP to higher levels of maternal hCG is based on both 
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NVP and hCG peaking at around 12 to 14 weeks of gestation.64 Furthermore, NVP is reported 
more commonly in pregnancies with elevated hCG levels, including multiple gestations, molar 
pregnancies, and pregnancies with female fetuses,65 and hCG levels correlate with severity of 
NVP 66. NVP may also serve as a proxy for progesterone levels.67 High progesterone levels are 
necessary to maintain a successful pregnancy,68 and higher progesterone levels are associated 
with NVP, potentially because of its effects on smooth muscle relaxation and consequent gastric 
dysrhythmia.67 
 
NVP may also serve as a marker for length of gestation, which is itself associated with viability 
of the pregnancy, again resulting in reverse causation. NVP peaks late in the first-trimester when 
most pregnancy losses have already occurred. Thus, pregnancies ending in early losses have less 
time at risk for NVP and their time at risk occurs when NVP is less prevalent; however, 
pregnancies ending in live births have greater time at risk for NVP and this time at risk 
encompasses the period of high NVP prevalence. This differential time at risk for NVP may 
explain the association between absence of NVP and loss. If one considered the effect of NVP 
during the early first trimester when losses are most likely to occur and NVP is relatively less 
common across all pregnancies, one may see a different relationship between NVP and loss 
(possibly, a null association). 
 
Limitations of existing literature on signs and symptoms of pregnancy loss 
 
Cumulative incidence of hCG pregnancy loss (~ 25-33%)4,10,11,14 is roughly double the 
cumulative incidence of clinically recognized pregnancy loss (~10-15%).4,10,11,14 Thus, in 
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pregnancy cohort studies many of the pregnancy losses occurring early in gestation were either 
not captured at all or data on signs and symptoms were ascertained after the loss was recognized. 
Therefore, data from these pregnancy cohorts must be interpreted with caution, as the incidence 
of signs and symptoms likely did not include early losses in either the numerator (number of 
losses) or the denominator (number of pregnancies). Of note, I only included studies that 
attempted prospective ascertainment of signs and symptoms to limit recall bias i.e., studies 
involving data collection that preceded the ascertainment of the pregnancy loss. However, the 
day of loss was often unknown, and thus, data on signs and symptoms may have been collected 
after the loss of the pregnancy but prior to loss recognition. 
 
As healthier pregnancies tend towards longer gestations than unhealthy pregnancies, pregnancy 
cohorts capture more healthy pregnancies and fewer unhealthy pregnancies than the underlying 
source population of all pregnancies, resulting in length-biased sampling. The pregnancies 
observed in typical pregnancy cohorts are less likely to end in a loss and possibly more likely to 
have signs and symptoms of pregnancy such as nausea and vomiting simply because of the 
gestational age at which signs and symptoms are ascertained. Results from these studies may not 
be applicable to very early pregnancy losses as the relationships between signs and symptoms 
and pregnancy loss may change across gestation. Furthermore, the reported associations may be 




Existing data provided some insights into the relationships between individual signs and 
symptoms and pregnancy loss among care-seeking populations with gestations that are well into 
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the first-trimester and beyond. These included the findings that vaginal bleeding was associated 
with an increased risk of pregnancy loss and that nausea and vomiting were associated with 
decreased risks of pregnancy loss. However, three notable data gaps exist. First, data are needed 
on early first trimester pregnancy losses, particularly those that would not normally reach clinical 
care but which comprise a large proportion of pregnancy losses. Second, data on multiple signs 
and symptoms captured simultaneously are needed to establish temporal patterns of signs and 
symptoms that may be concerning or reassuring for subsequent pregnancy loss and to allow 
empirical testing for time-varying effects of signs and symptoms on losses across gestation, e.g., 
are the relationships between signs and symptoms and loss consistent throughout gestation or do 
they vary by gestational age? Third, detailed data on gestational age at pregnancy discovery, loss 
ascertainment, loss to follow-up and birth are needed to employ survival analytic approaches to 
the signs and symptoms of pregnancy loss. To address these data gaps, preconception cohorts 
with detailed, prospectively collected data on multiple signs and symptoms and with uniform and 




Table 2.1.A. Literature search terms in PubMed/MEDLINE 
 
Applying the ‘prospective studies’, ‘English’, and ‘Humans’ MeSH term restrictions 
abortion, spontaneous (MeSH Term) and nausea (Title/Abstract) 
abortion, spontaneous (MeSH Term) and vomiting (Title/Abstract) 
abortion, spontaneous (MeSH Term) and cramping (Title/Abstract) 
abortion, spontaneous (MeSH Term) and bleeding (Title/Abstract) 
abortion, spontaneous (MeSH Term) and (symptoms (Title/Abstract) or signs (Title/Abstract)) 
fetal death (MeSH Term) and nausea (Title/Abstract) 
fetal death (MeSH Term) and vomiting (Title/Abstract) 
fetal death (MeSH Term) and cramping (Title/Abstract) 
fetal death (MeSH Term) and bleeding (Title/Abstract) 
fetal death (MeSH Term) and (symptoms (Title/Abstract) or signs (Title/Abstract)) 
pregnancy loss (Title/Abstract) and nausea (Title/Abstract) 
pregnancy loss (Title/Abstract) and vomiting (Title/Abstract) 
pregnancy loss (Title/Abstract) and cramping (Title/Abstract) 
pregnancy loss (Title/Abstract) and bleeding (Title/Abstract) 
pregnancy loss (Title/Abstract) and (symptoms (Title/Abstract) or signs (Title/Abstract)) 
 
Applying the ‘Humans’ and ‘English’ MeSH term restrictions 
miscarriage (Title/Abstract) and vaginal bleeding (Title/Abstract)  
miscarriage (Title/Abstract) and nausea (Title/Abstract)  
miscarriage (Title/Abstract) and symptoms (Title/Abstract)  
pregnancy loss (Title/Abstract) and pregnancy symptoms (Title/Abstract)  
 
Applying only the ‘English’ restriction   
Pregnancy Complications[MeSH Major Topic] AND bleeding[Title/Abstract] 
Pregnancy Complications[MeSH Major Topic] AND (vomiting[Title/Abstract] or 
nausea[Title/Abstract]) 




Table 2.1.B Literature search terms in Embase 
 
Applying the ‘English’, and ‘Humans’ limitations 
spontaneous abortion and nausea  
spontaneous abortion and vomiting  
spontaneous abortion and cramping  
spontaneous abortion and bleeding  
spontaneous abortion and (symptoms or signs) 
fetal death and nausea  
fetal death and vomiting  
fetal death and cramping  
fetal death and bleeding  
fetal death and (symptoms or signs) 
pregnancy loss and nausea  
pregnancy loss and vomiting  
pregnancy loss and cramping  
pregnancy loss and bleeding  
pregnancy loss and (symptoms or signs) 
miscarriage and vaginal bleeding  
miscarriage and nausea  
miscarriage and symptoms  
pregnancy loss and pregnancy symptoms  
Pregnancy Complications AND bleeding 
Pregnancy Complications AND (vomiting or nausea) 






1997 34  
Peckham









ulative incidence of vaginal bleeding and associations w






test at a general 
practice in England 
w





ended (loss or 






























bleeding ≤6 days 
and ≥7 days 
from


















































































































did not have 









































et al., 2003 
33 
C
are-seeking cohorts (continued) 
First 
author, 




ulative incidence of vaginal bleeding and associations w











in a trial for trisom
y 







ith a viable 
fetus on routine 
ultrasound scan at 6-















bleeding in the 4 
w











































































































































































al., 2009 37 
H
arville et 











ulative incidence of vaginal bleeding and associations w










) or prior to 




























study size (n) 
Self-report of all 















ithin 4 days of loss;  






reporting after loss. 
Self-report of any 




















































































































































































ny vs no 
R
R
: 0.9  
(0.8, 1.1)  
 H
eavy vs no 
R
R
: 2.0  








































ulative incidence of nausea and vom
iting in pregnancy and associations w









participating in a 
study (n=7,027). 
Patients in a general 
practice in rural 
Israel (n=100). 


























































































































































































































al., 1986 43 
K
lebanoff 
















ulative incidence of nausea and vom
iting in pregnancy and associations w













ho had ongoing 


























































































































































































































































0.5 (0.2, 0.9) 






















































ulative incidence of nausea and vom
iting in pregnancy and associations w



















prenatal care at a 

























































































































































































































































charts had a 


















































































ulative incidence of nausea and vom
iting in pregnancy and associations w
ith pregnancy loss  (cont.) 
W
om






prior to pregnancy 





test (n=2,407).   
W
om









ith data on nausea 




























report of nausea 
including 









































































ith nausea in 
the first 
trim





















































































ulative incidence of nausea/vom
iting in the setting of vaginal bleeding and associations w
ith pregnancy loss 
Patients w




 presenting to 
hospital in Singapore w
ere 
follow
ed until 16 w
eeks 
gestation for loss (n=139). 
Patients in a general practice 
in rural Israel w
ith 





ent of bleeding, and 
study size (n) 
Self-report of 






















































































had a loss. 
0%


























































































Number of records after duplicates 
removed 
n=16,804 
Number of records passing title 
review 
n=112 
Number of full-text articles 
assessed for eligibility 
n=45 
Total number of studies included 
in systematic review 
n=18 
Number of records removed 
through title review 
n=16,692 
Number of records removed 
through abstract review 
n=67 
Number of full-text articles 
excluded, with reasons 
n=29 
Number of additional articles 
identified through reference 
lists and systematic reviews 
n=2 
Number of full-text articles 
included in systematic review 
n=16 










CHAPTER 3: SIGNS AND SYMPTOMS ASSOCIATED WITH EARLY PREGNANCY 




The objective of this study was to assess the relationships between signs and symptoms of early 
pregnancy and pregnancy loss <20 weeks gestation using a population-based preconception 
cohort of 501 couples discontinuing contraception to try for pregnancy in 16 counties in 
Michigan and Texas, USA. Participants were followed daily until positive home pregnancy test 
or 12 months of trying without an hCG pregnancy; women who became pregnant recorded daily 
from 2 to 7 weeks post-conception their signs and symptoms, including vaginal bleeding (none, 
spotting, light, moderate, heavy), lower abdominal cramping, nausea, and vomiting, which were 
classified as any/none during the early pregnancy period. Individual signs and symptoms, their 
combinations, and their temporal patterning were evaluated in relation to pregnancy loss. 
Pregnancy losses were ascertained by a conversion to a negative home pregnancy test, clinical 
confirmation, or onset of menses, depending on gestational age at demise; time-to-loss was 
measured in days post-conception. Cumulative incidence functions and 95% confidence intervals 
were constructed for each sign or symptom, and hazard ratios and 95% confidence intervals for 
presence compared with absence of signs or symptoms were estimated using Cox proportional 
hazard models. 
 
Ninety-five (28%) women experienced a loss. Women experienced lower abdominal cramping 
(85%), nausea (48%), vomiting (46%), and light/moderate/heavy vaginal bleeding (24%) during 
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early pregnancy. Ten percent of women experienced no vomiting, cramping, or bleeding, 36% 
experienced cramping only, 26% experienced cramping with vomiting, 8% experienced 
cramping with bleeding, and 15% experienced all 3 symptoms. Cumulative incidence of 
pregnancy loss varied by individual signs and symptoms: 19% for vomiting, 27% for cramping, 
35% for nausea only, 50% for bleeding. Cumulative incidence of loss also varied by 
combinations of signs and symptoms: 10% for cramping with vomiting, 23% for cramping alone, 
34% for no symptoms, 36% for all 3 symptoms, and 81% for bleeding with cramping. Vaginal 
bleeding was associated with increased incidence of early pregnancy loss (HR 3.62, 95% CI 
2.29, 5.74), with more severe bleeding and bleeding with lower abdominal cramping associated 
with greater incidence of loss (HR 5.03, 95% CI 2.07, 12.20); conversely, vomiting was 
associated with a decreased incidence of early pregnancy loss (HR 0.51, 95% CI 0.30 to 0.86), 
while nausea alone was not. In the setting of vaginal bleeding with lower abdominal cramping, 
vomiting reduced the incidence of pregnancy loss (hazard ratio 0.24, 95% confidence interval 
0.11 to 0.56). 
 
By using sensitive home pregnancy tests, I was able to document and characterize the cumulative 
incidence of the earliest pregnancy losses, which constituted the majority of losses. The use of 
daily, prospective capture of signs and symptoms relative to ascertainment of pregnancy loss 
avoided potential biases associated with reporting after rather than before a loss, which could 
potentially distort the relationship between signs and symptoms and pregnancy loss. The findings 
of this study suggest that it may be useful to develop prognostic models for pregnancy loss based 
on signs and symptoms; such models may need to incorporate potentially time-varying effects of 





Pregnancy loss is common, affecting approximately one-third of pregnancies.4,14 However, 
among spontaneous conceptions, where the endpoints of fertilization and implantation are not 
readily visualized, loss is often unobserved. This problem contributes to our limited 
understanding of the earliest stages of pregnancy and human development. In fact, the natural 
history of pregnancy loss, including temporal ordering of signs and symptoms, has yet to be fully 
described. As reviewed in Chapter 2, there is a dearth of studies with prospectively collected 
information on the signs and symptoms of pregnancy loss. Valid data on signs and symptoms 
that portend pregnancy loss would be useful for women and clinicians to prompt medical care 
and evaluation for women experiencing concerning signs and symptoms. However, valid data 
can only be obtained from preconception studies, which is the only study design that facilitates 
the prospective ascertainment of the earliest signs and symptoms prior to any subsequent loss. 
 
Despite this, only two reported studies with preconception enrollment were identified in the 
literature. One study evaluated daily vaginal bleeding38 and non-specific pregnancy symptoms,69 
separately, in relation to pregnancy loss but was limited by the small number of losses (n=62).4 
Another study evaluated monthly reports of nausea in relation to loss but reporting often 
occurred after the loss.49 As signs and symptoms do not occur in isolation, studies describing 
multiple signs and symptoms simultaneously in relation to loss are needed to delineate the 
natural history of pregnancy loss. I identified three such studies in Chapter 2, all conducted 
among women seeking clinical care. Two were pregnancy cohort studies conducted in the 
1950s,41,42 while the other more recent study only recruited women presenting for evaluation of 
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bleeding during pregnancy.50  Thus, there is a distinct gap in the literature regarding the 
symptomatology associated with early pregnancy and early pregnancy loss for contemporary 
cohorts of women who are now able to recognize pregnancy earlier than previous birth cohorts; 
in the era of home pregnancy testing, many women may detect their pregnancies, and even early 
losses, before presenting for clinical care.70 Data are needed from non-clinical cohorts that can 
prospectively and continuously ascertain multiple signs and symptoms early in pregnancy and 
prior to loss ascertainment.   
 
I, therefore, undertook this study to examine the relationship between multiple signs and 
symptoms—vaginal bleeding, lower abdominal cramping, nausea, and vomiting—and pregnancy 
loss at less than 20 weeks gestation in a population-based preconception cohort of women. My 
objective was to describe the symptomatology of early pregnancy loss using a unique data set of 
pregnancies ascertained early using home pregnancy tests with daily prospective collection of 
signs and symptoms prior to pregnancy loss ascertainment. As the majority of early pregnancy 
losses occur prior to clinical care,4,49 this study cohort offered a unique opportunity to delineate 





Details of the recruitment strategy for the Longitudinal Investigation of Fertility and the 
Environment (LIFE) Study have been described elsewhere.71 Briefly, the LIFE Study was a 
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population-based, prospective, preconception cohort study of couples attempting pregnancy 
conducted from 2005-2009 in 16 counties in Michigan and Texas, USA. Couples who were 
planning to discontinue contraception to become pregnant and those who had been attempting 
pregnancy for ≤ 2 months were screened for study eligibility. Eligible couples were those who 
were married or in a committed relationship, in which both partners were able to communicate in 
English or Spanish, the male partner was aged 18 years or older, and the female partner was aged 
18-40 years, had a usual cycle length of 21-42 days, and no hormonal birth control injections in 
the past year. Couples who had clinically diagnosed infertility and those in which at least one 
partner was sterilized were excluded. All women had a urine-based pregnancy test administered 
at the baseline home interview to ensure they were not already pregnant and still at risk for 




At baseline interview, women reported their age, race/ethnicity, education, income, employment 
status, current smoking status, and reproductive history (past pregnancies, deliveries, and 
pregnancy losses). Study personnel measured the women’s height and weight using standardized 
protocols in order to calculate body mass index (BMI).72 
 
Ascertainment of conception  
In the absence of visualization of either ovulation or conception, we used proxy markers of 
ovulation and conception.  At study entry, women were instructed to use the urine-based digital 
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ClearBlue ™ Fertility Monitor consistent with the manufacturer’s guidance. The monitor records 
the ratios of estrone-3-glucuronide and luteinizing hormone and stores summary data for up to 6 
months. Study personnel downloaded the data every 45 days per the terms of a Disclosure 
Agreement with the manufacturer and Eunice Kennedy Shriver National Institute of Child Health 
and Human Development. The ClearBlue™ Fertility Monitor has been demonstrated to provide 
an accurate measure of ovulation compared with the gold standard, i.e., ultrasound visualization 
of ovarian follicles and ovulation.73 Day of ovulation was approximated by the peak day of 
luteinizing hormone as indicated by the fertility monitor. If two days of peak luteinizing 
hormone were indicated, the latter day was taken as the day of ovulation.73 For 59 women (17%) 
who did not have fertility monitor data available for the pregnancy cycle, data from the fertility 
monitor were available for other menstrual cycles within the same woman that did not end in 
pregnancy. The average day of ovulation from the prior cycles was imputed as the day of 
ovulation for the pregnancy cycle. For an additional 16 women (5%) with no fertility monitor 
information for any cycles in the study, ovulation was assumed to occur 14 days prior to the 
positive pregnancy test, consistent with the relatively more stable length of the secretory phase of 
the menstrual cycle compared with the proliferative phase.74 As previously suggested,75 the day 
of conception was approximated by the day of ovulation in keeping with the short viability of the 
ovum following ovulation.76 
 
Ascertainment of pregnancy 
Pregnancy was established by the urine-based home pregnancy test. All women were provided 
with ClearBlue™ Digital Pregnancy Test (Inverness Medical Innovations, Waltham, MA) kits 
and multiple urine test sticks for each cycle. Women were instructed to test on the day of 
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expected menses. If the test was positive, they were instructed to test again one week after the 
first positive pregnancy test. If the pregnancy test on the day of expected menses was negative, 
women were instructed to test again in one week or if bleeding began. These instructions are 
consistent with manufacturer’s guidance. The test has an advertised hCG sensitivity of 25 
mIU/mL, though independent testing has shown that it can detect even lower concentrations of 
pure hCG and hyperglycosylated hCG, the predominant forms of hCG in early pregnancy.73 The 
digital readout of ‘pregnant’ and ‘not pregnant’ removed subjectivity in interpreting the results 
associated with symbols or colored lines. Women recorded daily whether they took a pregnancy 
test and the result of the test. One positive urine pregnancy test denoted an hCG pregnancy.  
 
Ascertainment of signs and symptoms  
Signs and symptoms of pregnancy and associated loss were recorded daily for five weeks 
beginning on the day after the positive pregnancy test (~2 to 7 weeks post-conception). If women 
experienced a pregnancy loss during that interval, only information on signs and symptoms 
occurring before the day of event were used. Vaginal bleeding was recorded as none, spotting, 
light, moderate, or heavy using standardized pictographs.77 Lower belly cramping was recorded 
as present or absent. Nausea and vomiting were recorded as none, nausea only, vomiting only, or 
both nausea and vomiting. Women had the option of completing journals online daily or on 
hardcopy. If the former, women could not edit previously submitted data unless they notified the 
data coordinating center they made a mistake. If the latter, women were instructed to not backfill 
any days they missed; they were instructed to leave those days missing. The hardcopy journals 
queried daily for one week before the postcard with information was returned. Research 
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assistants monitored the web based data collection system to ensure cards were returned in a 
timely manner.   
 
Ascertainment of pregnancy loss  
Pregnancy loss was defined as conversion of a positive pregnancy test to a negative pregnancy 
test, clinical confirmation, or onset of vaginal bleeding consistent with expulsion of the products 
of conception.78 More details are provided in Appendix A. Early pregnancy loss was defined as a 
loss of an hCG pregnancy <20 weeks gestation. Ectopic pregnancies and pregnancy losses 




Several descriptive analyses were undertaken to understand the data. Given the multiple methods 
by which women could ascertain their losses depending upon gestational age, I assessed potential 
differences in day of positive pregnancy test, day of pregnancy loss ascertainment, and maternal 
characteristics by loss ascertainment method. I also examined the maternal characteristics of 
women included in the analytic cohort.  
 
Multiple imputation of signs and symptoms 
Despite the intensity of daily collection of signs and symptoms, the daily journal data were 
mostly complete. Seventy-six percent of women were missing less than 30% of daily bleeding 
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data, and fifty-nine percent of women were missing less than 30% of daily cramping, nausea, and 
vomiting data. Any missing daily data on signs and symptoms were imputed using the multiple 
imputation ‘mice’ package in the R software.79 One hundred imputed data sets were generated. 
For each sign or symptom, all available data were used for the imputation, including maternal 
characteristics, other days of information on the sign or symptom, and other signs or symptoms. 
More detail is provided in Appendix B. Any imputed data occurring on or after the day of 
pregnancy loss or loss to follow-up were set to missing. 
 
Cumulative incidence of signs and symptoms 
Cumulative incidence functions (CIF) of pregnancy loss across gestation were constructed based 
on the imputed data.80 CIF of loss by the presence and absence of the individual signs and 
symptoms, their severity, combinations, and patterns were constructed over time anchored to 
post-conception gestational age. As our definition of pregnancy loss only included losses <20 
weeks gestation, any women with births or loss to follow-up after 20 weeks were censored at 140 
days post-last menstrual period (LMP) or 125 days post-conception (assuming conception 
occurred 15 days post-LMP, which is 14 days prior to median positive pregnancy test at cycle 
day 29). Rubin’s rules were used to combine CIF estimates and 95% confidence intervals (CI) 
across imputations. The log-log transformation was applied to 95% CI to ensure the resulting 






Signs and symptoms, combinations, and patterns of losses 
The following categories were created for individual signs and symptoms and their severity: any 
cramping versus none; any bleeding (spotting, light, moderate, heavy bleeding) versus none; any 
light, moderate, heavy bleeding versus none/spotting only; any moderate/heavy bleeding versus 
none/spotting/light bleeding; any nausea and/or vomiting versus no nausea and/or vomiting; any 
vomiting (with or without nausea) versus no vomiting; and any vomiting (with or without 
nausea) versus nausea alone. ‘Any’ refers to the presence of the sign or symptom on one or more 
days during the early pregnancy period. 
 
CIF were also constructed for combinations of three signs and symptoms: bleeding, vomiting, 
and cramping. Combinations that were considered positive for bleeding included women with 
one or more days of light, moderate, or heavy bleeding (women with spotting only were 
considered negative for bleeding). Combinations that were considered positive for vomiting 
included women with one or more days of vomiting (with or without nausea); women with 
nausea only were considered negative for vomiting. I fully explored all combinations of signs 
and symptoms and found that five combinations were sufficient for analysis: no bleeding/ 
cramping/vomiting, cramping alone, cramping with vomiting, cramping with bleeding, cramping 
with vomiting and bleeding. All other combinations were too sparse for stable estimates (<5% of 
imputations). Several reference groups were specified in individual models to better understand 
the relative hazards of combinations of symptoms relative to no symptoms, the most common 
symptom cramping only), and the combination of symptoms associated with highest risk of loss 
(cramping with bleeding). 
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I also examined the temporal order of the three signs and symptoms in relation to one another. 
The five combinations of the three signs and symptoms listed above yielded over two-dozen 
possible temporal patterns. I only analyzed patterns with sufficient sizes to allow for stable 
estimates (≥5% of imputations). These patterns were no bleeding/cramping/vomiting, cramping 
only, cramping followed by vomiting without bleeding, cramping followed by bleeding without 
vomiting, cramping followed by vomiting followed by bleeding, cramping following by bleeding 
followed by vomiting. Two reference groups were specified in individual models to better 
understand the relative hazards of combinations of symptoms relative to no symptoms and the 
pattern of symptoms associated with highest risk of loss (cramping followed by bleeding without 
vomiting). 
 
Regression modeling of signs and symptoms and pregnancy loss 
Cox proportional hazards models were used to estimate hazards ratios (HR) and 95% confidence 
intervals (CI) for individual signs and symptoms, combinations, and temporal patterns in relation 
to pregnancy loss. We examined all maternal characteristics for evidence of confounding; that is, 
characteristics associated with each sign or symptom and associated with loss among women 
without each sign or symptom. None of the characteristics met these criteria. We did not conduct 
any subgroup analyses as our objective was to describe the natural history of signs and 
symptoms of pregnancy loss among the entire population of women with an hCG pregnancy in 
this preconception cohort. As with the estimation of CIFs, post-conception gestational age was 
used as the anchor for survival time with censoring at 125 days for women who gave birth or 
were lost to follow-up ≥20 weeks gestation. Estimates were combined across imputations using 
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Rubin’s rules implemented with PROC MIANALYZE in SAS version 9.4. I tested the 
proportionality assumption of the Cox proportional hazard model using a time-dependent 
covariate for the individual signs and symptoms, combinations, and patterns. Only 
moderate/heavy bleeding was time-dependent. On graphically assessing the non-proportionality 
by comparing the CIF graphs for time-to-loss, I did not detect extreme deviation from the 
proportionality assumption. As the Cox proportional hazard model is reasonably robust to the 





Of the 501 women enrolled, 347 became pregnant including 3 twin pregnancies. 341 remained in 
the study population after excluding 3 ineligible losses (Figure 3.1). Ninety-five (28%) women 
met the definition of having a pregnancy loss <20 weeks, 203 (60%) pregnancies ended in live 
birth, 24 (7%) in loss to follow-up before 20 weeks, and 19 (6%) in loss to follow-up after 20 
weeks gestation.  
 
The characteristics of 341 women are presented in Table 3.1. Almost half the women were aged 
thirty years or older (46%), the majority were non-Hispanic white (84%), had attended college 
(96%), had annual household incomes ≥$50,000 (87%), were employed (80%), were overweight 
or obese (50%), were recruited from Texas (81%), and did not smoke at study entry (93%). 
Thirty-nine percent of women had not been pregnant previously. Of 209 women with ≥1 
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previous pregnancies, 87% had ≥1 prior deliveries and 33% had ≥1 prior pregnancy losses 
(categories not mutually exclusive as women could have more than one prior pregnancy).  
 
Median cycle day of first positive pregnancy test was day 29; this was the same for women with 
and without pregnancy loss (Appendix C). Among 95 women with losses, there were no 
differences in maternal characteristics of age, race/ethnicity, education, income, employment 
status, current smoking status, BMI, or reproductive history by the method of loss ascertainment 
(Appendix D). As expected, day of loss ascertainment differed by ascertainment method: losses 
at the earliest gestational ages were ascertained by bleeding pattern and negative pregnancy test, 
while losses at later gestational ages were ascertained by inaudible heartbeat and ultrasound 
confirmed fetal demise. 
  
Cumulative incidence of signs and symptoms and relation to loss  
A total of 335 (98%) women had one or more days of information on signs and symptoms 
between the positive pregnancy test and pregnancy outcome and were included in modeling. Of 
these 335 women, only 2% reported complete absence of any signs or symptoms during early 
pregnancy. Any nausea and/or vomiting was the most common symptom (94%); cumulative 
incidence of vomiting was 46% (Table 3.2). Cramping was also common affecting 85% of 
women. Cumulative incidence of any bleeding was 43%; cumulative incidence of bleeding 
exclusive of spotting was 24%. Ninety-nine percent of women had combinations of signs and 
symptoms that fell into the combinations modeled (Table 3.3). Eighty-seven percent of women 
had patterns that fell into the six patterns modeled; cramping only (36%), cramping followed by 
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vomiting without bleeding (24%), and no cramping/vomiting/bleeding (no symptoms) (10%) 
were more common than the three patterns with bleeding (5-6% each, Table 3.4).   
 
Cumulative incidence functions 
The overall CIF of loss for the sample is presented in Figure 3.2. The rate increased sharply from 
two (2%) to three weeks (10%) post-conception, and continued to rise until 10 weeks post-
conception (27%) before plateauing at 14 weeks (28%). The expectation for the incidence of 
pregnancy loss in the absence of any additional information on signs and symptoms was 28% 
and could be regarded as a baseline cumulative incidence of early pregnancy loss <20 weeks 
gestation.  
 
Figure 3.3 shows the CIF of pregnancy loss by presence or absence of any cramping; the 
incidence of loss was similar among women with and without cramping (~30%). Figure 3.4.A 
shows the CIF of loss for women with any versus no bleeding; a higher incidence of loss was 
observed among women with (~40%) than without bleeding (~20%). Figures 3.4.B and 3.4.C 
show the CIF of loss by severity of bleeding; incidence of loss exceeded 50% among women 
with more severe bleeding. The CIFs of loss by any and no nausea/vomiting are shown in Figure 
3.5.A with similar incidence of loss among women with and without nausea/vomiting (~30%). 
Figures 3.5.B and 3.5.C show the CIF of loss by intensity of nausea/vomiting: none, nausea only, 
and any vomiting. Women with any vomiting had lower incidence of loss (~20%) than women 




Figure 3.6 shows the CIF for the combinations of signs and symptoms. For women experiencing 
all three symptoms, the cumulative incidence of loss (~35%) was similar to the cumulative 
incidence of loss among women experiencing none of the three symptoms (~35%), which was 
only slightly greater than the baseline incidence of loss for the study population (~30%). 
However, when examined individually or in dual combinations, women with cramping only 
(~25%) and cramping with vomiting (~10%) had lower incidence of loss than comparison 
women. Women with bleeding and cramping had a markedly higher incidence of loss (~80%).  
 
Figure 3.7 shows the CIF of loss for various patterns of signs and symptoms. Similar to Figure 
3.6, the highest incidence of loss was observed for cramping with bleeding without vomiting 
(~80%) and the lowest incidence was for cramping with vomiting without bleeding (~10%). 
Cramping followed by bleeding followed by vomiting, and cramping followed by vomiting 
followed by bleeding had similar incidences of loss (~40%).  
 
Cox proportional hazards models  
Results of Cox proportional hazards models with individual signs and symptoms are presented in 
Table 3.5. Vaginal bleeding was associated with an increased incidence of pregnancy loss while 
vomiting was associated with a decreased incidence of pregnancy loss. Specifically, any versus 
no bleeding was associated with a higher incidence of loss (HR 2.65, 95% CI: 1.70 to 4.14). 
Similarly, light, moderate, or heavy bleeding versus none or spotting only (HR 3.62, 95% CI: 
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2.29 to 5.74) and moderate or heavy bleeding versus none, spotting, or light bleeding (HR 4.22, 
95% CI: 2.53 to 6.69) were associated with an increased incidence of loss. Compared with no 
nausea and/or vomiting, nausea alone was not associated with pregnancy loss. However, any 
vomiting was inversely associated with loss compared with none (HR 0.51, 95% CI: 0.30 to 
0.86) or compared with nausea alone (HR 0.50, 95% CI: 0.29 to 0.85). Presence compared with 
absence of cramping was not associated with loss. 
 
Results of the Cox proportional hazards models with combinations of signs and symptoms are 
presented in Table 3.6 and show that signs and symptoms co-occurring with cramping were 
associated with variations in the incidence of pregnancy loss. Specifically, compared with no 
symptoms, cramping with vomiting was inversely associated with loss (HR 0.27, 95% CI: 0.10 
to 0.78). Cramping with bleeding was positively associated with loss compared with no 
symptoms (HR 5.03, 95% CI: 2.07 to 12.20) or compared with cramping only (HR 7.26, 95% CI: 
3.52 to 14.98). Cramping only, cramping with vomiting, and cramping with vomiting and 
bleeding were associated with lower incidences of pregnancy loss relative to cramping with 
bleeding.  
 
Results of Cox proportional hazards models with various patterns of signs and symptoms are 
presented in Table 3.7 and reflect similar relationships to those seen with combinations of signs 
and symptoms. Compared with no symptoms, cramping followed by vomiting without 
subsequent bleeding was inversely associated with loss (HR 0.28, 95% CI: 0.10 to 0.82), while 
no association was observed for cramping followed by vomiting followed by bleeding. 
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Compared with no symptoms, cramping followed by bleeding without subsequent vomiting was 
positively associated with loss (HR 5.01, 95% CI: 1.84 to 13.67). Compared with cramping with 
bleeding without subsequent vomiting, cramping followed by bleeding followed by vomiting 
was inversely associated with loss (HR: 0.29, 95%CI: 0.09 to 0.96), as were cramping followed 
by vomiting followed by bleeding, cramping followed by vomiting without subsequent bleeding, 





In this population-based preconception study of women who ascertained their pregnancy status 
using sensitive home pregnancy tests, multiple signs and symptoms were often reported in early 
pregnancy (approximately 2-7 weeks post-conception) and differed by pregnancy outcome. 
Lower abdominal cramping appeared to be the norm rather than the exception during early 
pregnancy, and cramping was not associated with pregnancy loss per se. Vaginal bleeding was 
associated with a higher incidence of pregnancy loss, and severe bleeding was associated with 
higher loss rates. Vomiting was associated with lower incidence of pregnancy loss, though 
nausea alone was not. Compared with cramping alone, cramping accompanied by bleeding was 
associated with the highest incidence of pregnancy loss; in contrast, cramping with vomiting was 
associated with the lowest incidence of pregnancy loss. For women with cramping followed by 
bleeding, the incidence of pregnancy loss was lower if vomiting occurred subsequently than if 
vomiting did not occur.  For women with no cramping/vomiting/bleeding, the incidence of loss 




A notable strength of this work was that it utilized data from the largest prospective 
preconception cohort of couples who were followed daily82 from enrollment through 7 weeks 
post-conception irrespective of pregnancy outcome. Second, highly sensitive home pregnancy 
tests were used to ascertain pregnancy status. Urine-based home pregnancy testing was less 
burdensome on participants than serial urine collection, was less costly, captured more 
pregnancies than waiting for clinical confirmation, and provided real-time feedback to couples. 
Third, offering women multiple methods by which to record a loss minimized the under-
ascertainment of losses across all gestational ages. Importantly, all losses were recognized by the 
woman; none were ‘silent’ losses. I was therefore able to document and characterize the 
cumulative incidence of the earliest pregnancy losses, which constitute the majority of losses. 
Fourth, the study design allowed for the daily, prospective capture of signs and symptoms 
relative to ascertainment of pregnancy loss. This minimized potential biases associated with 
reporting after rather than before a loss, which could potentially distort the relationships between 
signs and symptoms and loss. While one cannot be certain that hardcopy journals were 
completed each day, I do not believe reporting differences varied by pregnancy outcome. Finally, 
I had a close proxy for the day of conception using fertility monitor data to ascertain the day of 
ovulation. Thus, I was able to use post-conception gestational age in survival analyses, which 
was a more precise measure of gestational duration than menstrual-based gestational age. 
 
Study limitations included few losses beyond 14 weeks gestation because of the relatively small 
study size. Thus, the precision of the findings related to losses occurring after the first trimester 
was limited. Second, by study design, information on signs and symptoms was only collected 
daily from 2-7 weeks post-conception gestation consistent with the embryonic period of 
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development. Third, there were relatively small numbers within each pattern of signs and 
symptoms given the large numbers of possible patterns. Fourth, while women were instructed to 
test for pregnancy on the day of expected menses, the pregnancy test can detect pregnancies as 
soon as eight days after the luteinizing hormone surge.83 There may be some biological variation 
in timing of positive pregnancy test relative to ovulation; however, measurement error of the 
proxy day of conception is unlikely to create substantial bias in our results given the small 
numbers of women impacted in our sample. Though small (7%), there was loss to follow-up 
prior to 20 weeks gestation in the study; this was addressed using a survival analytic censoring 
approach and available data was included in the study. Finally, there is some missing data on 
signs and symptoms. I did not find any statistically significant differences in the amount of 
missing information by the maternal characteristics that were used to inform the multiple 
imputation models. This provides some reassurance that the data are missing-at-random, which is 
an assumption challenging to verify in practice. Including several variables in the imputation 
model, as I did, also makes the missing-at-random assumption more plausible.84 Furthermore, I 
generated 100 imputed dataset consistent with the amount of missing data.85 
 
Given the amount of daily data available, I carefully considered which days of signs and 
symptoms to include in the analysis. I chose to include all of the days prior to the day of loss 
ascertainment for two reasons. First, understanding of the causes of pregnancy loss and the 
biologic mechanisms by which a pregnancy is spontaneously terminated is still very much 
unknown. Thus, one cannot say with any certainty that signs or symptoms occurring prior to a 
certain period before loss ascertainment are causes of loss while signs or symptoms occurring 
within a certain period of loss ascertainment are consequences of loss. Another serious concern 
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with excluding data on symptoms is that it would differentially impact early losses and bias the 
resulting estimates. Thus, I decided to include all data on signs and symptoms up until the day of 
loss ascertainment, acknowledging that day of loss ascertainment is an imperfect proxy for day 
of loss. 
 
I did not categorize loss by gestational age in light of no uniformly agreed upon approach, 
particularly for non-clinical populations for whom most pregnancies and losses are observed 
only by the woman, and in the absence of a clear understanding of the etiology of pregnancy loss 
across gestation. The analyses presented here address the average impacts of signs and symptoms 
in early pregnancy on subsequent pregnancy loss irrespective of timing. 
 
Few prior studies were able to evaluate multiple signs and symptoms in relation to pregnancy 
loss, and none explicitly examined lower abdominal cramping. Two pregnancy cohort studies in 
the 1950s41,42 and a more recent study on threatened abortion50 reported that in the setting of 
bleeding, nausea and/or vomiting was protective against pregnancy loss. Results presented in this 
Chapter were similar; however, in this study only vomiting was protective against loss in the 
setting of bleeding with cramping, while nausea was not.  
 
Another pregnancy cohort study reported that the risk of pregnancy loss was greatest in women 
with heavy bleeding and pain.37 I also found that the combination of bleeding with cramping was 
associated with the highest incidence of loss when it occurred without vomiting. A new finding 
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in this study was the high prevalence of lower abdominal cramping and the observation that 
cramping was not associated with loss unless accompanied by other signs or symptoms. 
Cramping accompanied by bleeding was associated with increased risk of loss; conversely, the 
risk of loss was decreased when cramping was accompanied by vomiting. This may suggest that 
the documentation of lower belly cramping in the daily journals captured a symptom that may 
have heterogeneous causes. Cramping that accompanies bleeding may reflect menstrual-type 
cramps that would be associated with the expulsion of the products of conception.78  Uterine 
cramping associated with vomiting may be a different entity since uterine contractility is 
associated with higher estrogen levels, which are associated with a healthy and developing 
gestation.86 Future epidemiologic studies may be able to ascertain the severity and typology of 
cramping in early pregnancy in more detail and more completely describe its relation to 
pregnancy loss. 
 
Evaluating the temporal patterns of signs and symptoms in relation to loss was also novel. For 
women experiencing cramping and bleeding, subsequent vomiting was a significant prognostic 
indicator; women without subsequent vomiting were at increased risk of loss while women with 
subsequent vomiting were not. Collectively, these findings underscored the need to evaluate 
multiple signs and symptoms simultaneously, reflecting the co-occurrence of these symptoms for 
many women. For example, in this analysis, 85% of women had one or more symptoms; 40% of 




Given the high frequency of lower abdominal cramping in early pregnancy and the lack of an 
association with pregnancy loss absent other co-occurring symptoms, it may be important to 
distinguish between different types of cramping, if such distinctions exist and can be made. In 
this study, the daily journals simply inquired about lower belly cramping and did not further 
qualify such as by severity or typology (e.g., menstrual-like cramps). While uterine quiescence is 
required for successful implantation of the embryo,87 in the weeks following implantation uterine 
contractility may be associated with a healthy pregnancy. Potentially, this may be due to the 
effects of estrogen, which is associated with uterine contractility87 and with ongoing pregnancy.86 
Cramping with bleeding likely reflects the expulsion of products of conception.78 However, it is 
possible that bleeding is the cause, rather than the consequence, of pregnancy loss. Subchorionic 
hemorrhage, often associated with vaginal bleeding, may cause oxygen-rich blood to invade the 
intervillous space prematurely, interfering with trophoblast development,56 or causing chronic 
inflammation, inducing myometrial contractions and expulsion of the gestational sac.56  
 
In contrast to vaginal bleeding, vomiting in early pregnancy appeared to be protective against 
pregnancy loss. This is consistent with the hypothesis that caloric restriction consequent to 
vomiting in early pregnancy causes maternal levels of insulin and insulin growth factor-1 (IGF-
1) to fall.60 Maternal anabolic processes are thereby inhibited and nutrient partitioning favors 
placental development. Nausea may not cause caloric restriction to the same extent as vomiting, 
and the cascade described above would not be initiated. Alternatively, vomiting may serve as a 
proxy for high progesterone levels, which are necessary to maintain a successful pregnancy,68 
and are also associated with NVP, potentially through its effects on smooth muscle relaxation 
and consequent gastric dysrhythmia.67 Visualized endpoints, such as embryo quality among 
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embryos being transplanted in assisted reproductive technology procedures, may be helpful in 






Though common in early pregnancy, lower abdominal cramping was not associated with 
pregnancy loss absent other signs and symptoms. Vomiting and nausea were also common in 
early pregnancy, and vomiting, but not nausea, was associated with a lower incidence of loss. 
While bleeding was less common in early pregnancy, it was associated with a higher incidence 
of loss, particularly if accompanied by lower abdominal cramping, though if vomiting 
subsequently followed bleeding the incidence of loss was less than if vomiting remained absent. 
The findings of this study suggest that it may be useful to develop prognostic models for 
pregnancy loss based on signs and symptoms; such models may need to incorporate potentially 
time-varying effects of signs and symptoms on pregnancy loss, which will be explored in the 
Chapter 4. More complete knowledge of the physiologic response of the body to early pregnancy 
will also enhance our understanding of the causes of each sign and symptom and its relation to 





Table 3.1. Characteristics of women included in the study population (n=341) 
 n (%) a 
Age  
   18-24 years old 25 (7) 
   25-29 years old 158 (46) 
   30-34 years old 114 (33) 
   35-40 years old 44 (13) 
Race/Ethnicity  
   Non-Hispanic White 283 (84) 
   Non-Hispanic Black 6 (2) 
   Hispanic 29 (9) 
   Other 20 (6) 
Education  
   High school or less 15 (4) 
   Some college or more 322 (96) 
Income  
   <$50,000 44 (13) 
   $50,000-99,999 161 (48) 
   $100,000+ 127 (38) 
Employed  
   No 68 (20) 
   Yes 273 (80) 
Body mass index  
   <18.5 5 (1) 
   18.5-24.9 164 (48) 
   25.0-29.9 88 (26) 
   30.0+ 83 (24) 
Site  
   Michigan 65 (19) 





Table 3.1. Characteristics of women included in the study population (n=341) (cont.) 
 
 
≥1 Prior pregnancy  
   No prior pregnancy 132 (39) 
   Prior pregnancy 209 (61) 
≥1Prior delivery (among those with ≥1 prior pregnancy)  
   No prior delivery 27 (13) 
   Prior delivery 179 (87) 
≥1 Prior loss (among those with ≥1 prior pregnancy)  
   No prior loss 139 (67) 
   Prior loss 68 (33) 
Current smoker  
   No  318 (93) 
   Yes 23 (7) 
 Median (IQR) 
Cycle day of positive pregnancy test 29 (27, 32) 
 
 






a Does not add to 100% as some combinations too small for stable estimates and not included in 
modeling   
Table 3.2. Cumulative incidence of individual signs and symptoms and cumulative 
incidence of pregnancy loss by individual signs and symptoms 
 Cumulative incidence of 
sign or symptom, %  
Cumulative 
incidence of loss, % 
Any Bleeding   
   No  57  18 
   Yes 43  40 
Bleeding Severity   
  None/Spotting only 76 20 
  Light/moderate/heavy bleeding 24 52 
Bleeding Severity   
  None/Spotting/light bleeding 83 21 
  Moderate/heavy bleeding 17 57 
Any Cramping   
   No  15 31 
   Yes 85 27 
Any Nausea and/or Vomiting   
   No  6 30 
   Yes 94 27 
Nausea and/or Vomiting Severity   
   No nausea or vomiting 6 30 
   Nausea only 48 35 
   Any vomiting, with or without nausea 46 19 
Any Vomiting   
   No  54 34 




a No symptoms includes women without light/moderate/heavy bleeding, without vomiting, and 
without lower abdominal cramping  
 
  
Table 3.3. Cumulative incidence of combinations of signs and symptoms  and cumulative 
incidence of pregnancy loss by combinations of signs and symptoms 
 Cumulative incidence of sign 
or symptom, % a  
Cumulative 
incidence of loss, % 
No symptoms a  10 34 
Cramping only  36 23 
Cramping and vomiting  26 10 
Cramping and bleeding  8 81 




a No symptoms includes women without light/moderate/heavy bleeding, without vomiting, and 
without lower abdominal cramping   
Table 3.4. Cumulative incidence of patterns of signs and symptoms by loss status  and 
cumulative incidence of pregnancy loss by patterns of signs and symptoms 
 Cumulative incidence 
of sign or symptom, %  
Cumulative 
incidence of loss, % 
No symptoms a  10 34 
Cramping only  36 23 
Cramping followed by vomiting, no bleeding  24 11 
Cramping followed by bleeding, no vomiting  5 81 
Cramping followed by vomiting followed by 
bleeding  
6 39 





Table 3.5. Cox proportional hazards models showing the association between individual 
signs and symptoms and pregnancy loss 
 Hazard Ratio (95% CI) 
Any cramping versus none 0.90 (0.46, 1.77) 
Any bleeding versus none 2.65 (1.70, 4.14) 
Light/moderate/heavy bleeding versus none/spotting only 3.62 (2.29, 5.74) 
Moderate/heavy bleeding versus none/spotting/light bleeding 4.22 (2.53, 6.69) 
Any nausea/vomiting versus none 0.93 (0.34, 2.56) 
Nausea only versus none 1.26 (0.45, 3.51) 
Any vomiting versus none 0.63 (0.22, 1.81) 
Any vomiting versus none/nausea only 0.51 (0.30, 0.86) 






Table 3.6. Cox proportional hazards models showing the association between combinations 
of signs and symptoms and pregnancy loss 
 Hazard Ratio (95% CI) 
No bleeding, no cramping, no vomiting a 1.00 (Referent) 
Cramping only 0.69 (0.30, 1.59) 
Cramping + Vomiting 0.27 (0.10, 0.78) 
Cramping + Bleeding 5.03 (2.07, 12.20) 
Cramping + Bleeding + Vomiting 1.21 (0.51, 2.89) 
  
Cramping only 1.00 (Referent) 
Cramping + Vomiting 0.39 (0.15, 1.03) 
Cramping + Bleeding 7.26 (3.52, 14.98) 
Cramping + Bleeding + Vomiting 1.75 (0.86, 3.56) 
  
Cramping + Bleeding 1.00 (Referent) 
Cramping only 0.14 (0.07, 0.28) 
Cramping + Vomiting 0.05 (0.02, 0.15) 
Cramping + Bleeding + Vomiting 0.24 (0.11, 0.56) 
 
a No bleeding, no cramping, no vomiting includes women without light/moderate/heavy 
bleeding, without vomiting, and without lower abdominal cramping   
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Table 3.7. Cox proportional hazards models showing the association between patterns of 
signs and symptoms and pregnancy loss 
 Hazard Ratio (95% CI) 
No bleeding, no cramping, no vomiting a 1.00 (Referent) 
Cramping only 0.69 (0.30, 1.59) 
Cramping followed by vomiting, no bleeding 0.28 (0.10, 0.82) 
Cramping followed by bleeding, no vomiting 5.01 (1.84, 13.67) 
Cramping followed by bleeding followed by vomiting 1.44 (0.46, 4.52) 
Cramping followed by vomiting followed by bleeding 1.29 (0.44, 3.78) 
  
Cramping only  1.00 (Referent) 
Cramping followed by vomiting, no bleeding 0.41 (0.15, 1.11) 
Cramping followed by bleeding, no vomiting 7.24 (3.04, 17.23) 
Cramping followed by bleeding followed by vomiting 2.08 (0.75, 5.81) 
Cramping followed by vomiting followed by bleeding 1.86 (0.73, 4.71) 
  
Cramping followed by bleeding, no vomiting 1.00 (Referent) 
Cramping only 0.14 (0.06, 0.33) 
Cramping followed by vomiting, no bleeding 0.06 (0.02, 0.18) 
Cramping followed by bleeding followed by vomiting 0.29 (0.09, 0.96) 
Cramping followed by vomiting followed by bleeding 0.26 (0.08, 0.79) 
 
a No bleeding, no cramping, no vomiting includes women without light/moderate/heavy 





Figure 3.1. Flowchart for the study population 
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Figure 3.3. Cumulative incidence of pregnancy loss, by cramping status estimates and 95% 



































Figure 3.4. Cumulative incidence of pregnancy loss by intensity of bleeding, estimates and 































































Figure 3.4. Cumulative incidence of pregnancy loss by intensity of bleeding, estimates and 


































Figure 3.5. Cumulative incidence of loss by severity of nausea/vomiting, estimates and 95% 
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Figure 3.5. Cumulative incidence of loss by severity of nausea/vomiting, estimates and 95% 




































































Cramping + Bleeding + Vomiting
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CHAPTER 4: TIME-VARYING EFFECTS OF SIGNS AND SYMPTOMS OF EARLY 





Pregnancy loss affects one-third of pregnancies, often causing psychological trauma to women 
and their partners; however, the signs and symptoms of pregnancy loss across gestation have yet 
to be fully described. Given the dynamic nature of maternal physiologic adaptation to early 
pregnancy progression, I posited that the relationships between signs and symptoms and 
subsequent pregnancy loss may change across gestational weeks. In a preconception cohort with 
daily follow-up, I evaluated the effects of weekly time-varying signs and symptoms on early 
pregnancy loss (n=95) in Cox proportional hazards models among 341 pregnancies ascertained 
using home pregnancy tests. The relationships between signs and symptoms and loss varied 
during the first five weeks following pregnancy confirmation. In the first week, vaginal bleeding 
(hazard ratio (HR) 8.67, 95% confidence interval (CI): 4.70, 16.01) and lower abdominal 
cramping (HR 1.80, 95% CI: 1.22, 2.65) were associated with increased loss, while in later 
weeks nausea and/or vomiting were inversely associated with loss (HR range 0.63 to 0.31, all 
95% CI upper bounds below 1.00). Presence of all three symptoms was associated with loss in 
the first week (HR 5.19, 95% CI: 2.56, 10.51) but not in later weeks. The relationships between 
signs and symptoms and pregnancy loss varied across early pregnancy possibly reflecting 





Pregnancy loss affects one in three pregnancies,4,14 potentially causing psychological distress to 
women and their partners.23,24,26 Despite the frequency and psychological trauma associated with 
early embryonic or fetal loss, the signs and symptoms of pregnancy loss across gestation have 
yet to be fully described. Doing so requires preconception studies by which the earliest losses, 
which constitute the majority of losses,4,14 can be captured and the signs and symptoms 
preceding loss can be prospectively ascertained. Furthermore, multiple signs and symptoms of 
pregnancy need to be collected and analyzed in relation to pregnancy loss as signs and symptoms 
often co-occur. 
 
However, the literature on the relationships between signs and symptoms and pregnancy loss is 
sparse, as reviewed in Chapter 2, and only includes two preconception studies.4,49 One 
preconception study of 221 women relied on laboratory measures of human chorionic 
gonadotropin (hCG) in serial urine collections to identify pregnancies (n=198) and losses (n=62), 
with most losses occurring prior to recognition by the woman.4 While presence of vaginal 
bleeding38 appeared to be associated with loss and non-specific pregnancy symptoms were 
inversely associated with loss,69 these associations did not achieve statistical significance likely 
owing to the small study size. Another study with the preconception recruitment of 585 women 
reported an inverse association between nausea and pregnancy loss; however, reporting on 
nausea occurred monthly and could occur after the loss, which was confirmed by the clinician.49 
In contemporary cohorts of women, most pregnancies are detected by the woman herself using 
sensitive urine-based home pregnancy tests,70 as was the case in this preconception study of 501 
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couples (described below). Such early detection of pregnancy means that many pregnancy losses 
are also ascertained by the women themselves prior to entering clinical care. As reported in 
Chapter 3, I observed significant associations between vaginal bleeding and pregnancy loss, 
particularly when accompanied by lower abdominal cramping, and an inverse association 
between vomiting and pregnancy loss.  
 
One important limitation of previous analyses on this issue, both the prior studies from the older 
preconception cohort studies38,49,69 and the results presented in Chapter 3 from this preconception 
cohort study, was the use of fixed effect covariates and fixed effect modeling to estimate the 
associations between signs and symptoms and pregnancy loss. However, the relationships 
between signs and symptoms and pregnancy loss may change during the early pregnancy period 
as maternal physiology rapidly adapts to the pregnancy. Therefore, I carried out a study to 
estimate the relationships between signs and symptoms and pregnancy loss using time-varying 





I used data from the Longitudinal Investigation of Fertility and the Environment (LIFE) Study, a 
population-based preconception cohort of 501 couples residing in 16 counties in Michigan and 
Texas, USA, 2005-2009. The LIFE Study has been described in detail elsewhere.71 Briefly, 
couples discontinuing contraception or off contraception ≤ 2 months in order to attempt 
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pregnancy were screened for eligibility. Eligibility criteria included being in a committed 
relationship, both partners communicated in English or Spanish, men were aged ≥18-years-old, 
women were aged 18-40 years-old, had menstrual cycle lengths of 21-42 days, and had not used 
injectable contraception within the past year. Couples in which one or both partners had 
physician-diagnosed infertility/sterility were ineligible. Enrolled couples were followed until a 
positive home pregnancy test or for 12 months of unsuccessful pregnancy attempts. After a 
positive home pregnancy test, women were followed until live birth or pregnancy loss. 
Institutional Review Board approval was obtained from all sites and all participants provided 
written informed consent. 
 
Study measures 
Maternal baseline characteristics 
 At enrollment, women were interviewed to ascertain sociodemographic, lifestyle, and 
reproductive health information including age, race/ethnicity, education, household income, 
employment status, smoking status, and previous pregnancies and pregnancy outcomes. Body 
mass index (BMI) was calculated from height and weight measured by study personnel using 
standardized protocols.72  
 
Ascertainment of pregnancy 
At enrollment, women were provided with the ClearBlue digital urine-based home pregnancy 
test kit (Inverness Medical Innovations, Waltham, MA) and multiple pregnancy test sticks for 
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each cycle. Women were instructed to test on the day of expected menses. If the test was 
positive, they were instructed to test again one week after the first positive pregnancy test. If the 
pregnancy test on the day of expected menses was negative, women were instructed to test again 
in one week or if bleeding began. These instructions were consistent with manufacturer’s 
guidance. The pregnancy test had an advertised hCG sensitivity of 25 IU/L, though independent 
testing showed that it can detect lower concentrations of pure hCG and hyperglycosylated hCG, 
the predominant forms of hCG in early pregnancy.83 The digital readout categorized the result 
into ‘pregnant’ or ‘not pregnant’ and removed subjectivity in interpreting the result. Women 
recorded pregnancy test results in daily journals while trying for pregnancy. A single positive 
pregnancy test denoted hCG pregnancy. The distribution and cumulative incidence of positive 
pregnancy test by cycle day are presented in Appendix E.  
 
Ascertainment of signs and symptoms 
 For five weeks following the first positive home pregnancy test, women recorded daily the 
occurrence of vaginal bleeding and its severity (none, spotting, light, moderate, heavy) using 
standardized pictographs.77 Women also recorded daily lower belly cramping (yes/no) and 
nausea and/or vomiting (none, nausea only, vomiting only, or both nausea and vomiting).  
 
Ascertainment of early pregnancy loss 
Pregnancy loss was ascertained by conversion of a positive pregnancy test to a negative 
pregnancy test, clinical confirmation of pregnancy loss, or onset of vaginal bleeding of an  
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intensity and pattern consistent with expulsion of the products of conception.78 More details are 
provided in Appendix A. Early pregnancy loss was defined as a pregnancy loss at <20 weeks 




The time-to-event was measured in days following a positive pregnancy test consistent with the 
timing when women were queried about the onset of signs and symptoms. Losses occurring prior 
to day 35 (5 weeks) post positive pregnancy test were coded as events on the observed day; 
losses to follow-up prior to day 35 were censored on that day. Pregnancy losses occurring ≥35 
days post positive pregnancy test were coded as events at day 35. Live births and losses to 
follow-up ≥35 days post positive pregnancy test were censored at day 35.   
 
Days post positive pregnancy test was chosen as the time-to-event as I was interested in 
assessing the time-varying effects of signs and symptoms of pregnancy loss using time-varying 
signs and symptoms and the survival time scale needed to be consistent with the scale for the 
time-varying effects. Given that signs and symptoms were collected after the positive pregnancy 
test and not before, the time-varying effects were estimated for the first five weeks after the 
positive pregnancy test; thus, the survival time was also required to be time post positive 
pregnancy test. The units of survival time needed to be at least as fine as the units for time-
varying effects. In this case, weeks were chosen for the time-varying effects, but because days 
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are at least as fine as weeks, I used days post positive pregnancy test for survival time. Since 
signs and symptoms were not collected prior to positive pregnancy test, there would have been 
no effect of signs and symptoms on loss during that period. 
 
Time-varying covariates 
The values for signs and symptoms varied for each of the five weeks following a positive 
pregnancy test. Individual signs and symptoms for each week were coded as any versus no 
bleeding, light/moderate/heavy bleeding versus none/spotting only, moderate/heavy bleeding 
versus none/spotting/light bleeding, any versus no cramping, any versus no nausea or vomiting, 
any vomiting versus no nausea or vomiting, nausea only versus no nausea or vomiting. 
Combinations of signs and symptoms co-occurring in the same week were also constructed. All 
combinations were explored and the five combinations with sufficient numbers for stable 
estimates were 1) nausea and/or vomiting, cramping, and bleeding, 2) nausea and/or vomiting 
and cramping, 3) nausea and/or vomiting alone, 4) cramping alone, and 5) no nausea and/or 
vomiting, cramping, or bleeding. The severity of bleeding included in the combinations was in 
two forms: any bleeding or light/moderate/heavy bleeding.  
 
Multiple imputation of signs and symptoms 
I explored the data for completeness. Despite the intensity of daily collection, the signs and 
symptoms data were mostly complete. Among women with ongoing pregnancy at the beginning 
of the week, at least one day of bleeding information was recorded for over 85% of women 
during the first 4 weeks following a positive pregnancy test and half of women in week 5. At 
76 
 
least one day of cramping and nausea/vomiting information was completed for one-quarter of 
women in week 1, rising to over 80% in weeks 2-4, declining to half in week 5. Any days with 
missing data were imputed using the multiple imputation ‘mice’ package in the R software,79 and 
100 imputed data sets were generated. For each sign or symptom, all available data were used for 
the imputation, including maternal characteristics, other days of information on the sign or 
symptom, and other signs or symptoms. More information is provided in Appendix B. Any 
imputed data occurring on or after the day of pregnancy loss or loss to follow-up were set to 
missing.  
 
Cumulative probabilities of pregnancy loss 
The cumulative probabilities and 95% confidence intervals (CI) of pregnancy loss by the 
presence and absence of individual and combinations of signs and symptoms during each week 
following a positive pregnancy test were estimated from Cox proportional hazards models. 
Analyses were carried out in each of the 100 imputed data sets with the final results obtained by 
combining the results of individual data sets using Rubin’s rules in PROC MIANALYZE in SAS 
version 9.4 to provide accurate estimates for standard errors and resulting 95% CI. 
 
Regression modeling with time-varying effects 
The censoring variable was recoded as binary: event if the outcome was a loss, censored if the 
outcome was a live birth or loss to follow-up (non-loss). The relative hazards of pregnancy loss 
were estimated for presence versus absence of time-varying individual and combinations of signs 
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and symptoms using Cox proportional hazards models with time-varying effects. The effects of 
signs and symptoms on relative hazards of pregnancy loss were allowed to vary within the 
regression model. A beta coefficient was estimated for each of the five weeks post pregnancy test 
using weekly time-varying covariates described above. Analyses were carried out in each of the 
100 imputed data sets with the final results obtained by combining the results of individual data 
sets using Rubin’s rules in PROC MIANALYZE in SAS version 9.4 to provide accurate 




Characteristics of analytic cohort 
Of 501 couples, 347 achieved an hCG pregnancy. Three couples had twin pregnancies and were 
excluded. One pregnancy loss ≥20 weeks gestation and two ectopic pregnancies occurred and 
were also excluded leaving 341 pregnancies. Ninety-five (28%) pregnancies ended in loss, 203 
(60%) in live birth, 24 (7%) in loss to follow-up before 20 weeks, and 19 (6%) in loss to follow-
up ≥20 weeks gestation. The majority of women were aged 25-34 years, non-Hispanic white, and 
employed, with some college, and an annual household income ≥$50,000. Most were also non-
smokers and overweight or obese. Of 209 women with ≥1 pregnancies before study enrollment, 
87% had ≥1 prior deliveries and 33% had ≥1 prior pregnancy losses (categories not mutually 





Weekly frequencies of signs and symptoms 
Five pregnancy losses and one loss to follow-up occurred the day after the positive pregnancy 
test and did not contribute any information to the analysis. At the beginning of week 1 post 
positive pregnancy test, 335 pregnancies were ongoing, 300 were ongoing at week 2, 288 at 
week 3, 283 at week 4, and 271 at week 5. Overall, prevalence of any bleeding was fairly stable 
between weeks 1-5 (range 16-22%); however, moderate/heavy bleeding became less common as 
gestation advanced, declining from 10% in week 1 to 1% in week 5 (Table 4.1). While any 
nausea and/or vomiting was also fairly stable (range 64-81%) prevalence of vomiting increased 
from 19% in week 1 to 32% in week 5. Prevalence of lower abdominal cramping decreased from 
72% in week 1 to 53% in week 5.  
 
The prevalence of signs and symptoms differed by loss status (Figure 4.1). In comparison with 
women whose pregnancies did not end in a loss, women with losses were more likely to 
experience any bleeding, light/moderate/heavy bleeding, or moderate/heavy bleeding with 
markedly higher prevalence in weeks 1 and 2. Any nausea and/or vomiting was slightly more 
common in women whose pregnancies subsequently ended in loss than those whose did not in 
the first week post positive pregnancy test; however, in weeks 2-5, any nausea and/or vomiting 
was more common in pregnancies that did not end in a loss. Vomiting was slightly more 
common among pregnancies ending in loss in weeks 1 and 2 but was higher among pregnancies 
not ending in loss in weeks 3-5. Any cramping was slightly more common in week 1 for 
pregnancies ending in loss; however, in weeks 2-5, cramping was more common among 
pregnancies not ending in loss.  
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Cumulative probabilities of pregnancy loss 
Cumulative probabilities of pregnancy loss, which can be interpreted as the risks of pregnancy 
loss, in the presence and absence of signs and symptoms each week are presented in Table 4.2. 
The risk of pregnancy loss in the presence of bleeding decreased from week 1 to week 5 (64% to 
13%) as did the risk of pregnancy loss in the absence of bleeding (20% to 11%). The risk of 
pregnancy loss decreased from week 1 to week 5 in the presence of vomiting (39% to 6%) or 
nausea (29% to 10%) while in the absence of either the risk of pregnancy loss was increased 
from week 1 to week 4 (20% to 33%) before falling in week 5 (23%). The risk of pregnancy loss 
decreased in the presence of cramping from week 1 to week 5 (31% to 7%) while the risk of 
pregnancy loss in the absence of cramping was more stable from week 1 to week 5 (21% to 
16%). 
 
Cumulative probabilities of pregnancy loss by combinations of signs and symptoms each week 
are presented in Table 4.3. The risk of pregnancy loss in the absence of any signs or symptoms 
was fairly stable from week 1 to week 5 (24% to 20%). The risk of pregnancy loss in the 
presence of cramping only was stable from week 1 to week 4 (15% to 16%) with an increased 
risk of pregnancy loss in week 5 (25%), though with wide confidence intervals (0% to 53%). The 
risk of pregnancy loss in the presence of nausea and/or vomiting only decreased slightly from 
week 1 to week 5 (18% to 11%) though with overlapping confidence intervals. The risk of 
pregnancy loss in the presence of nausea and/or vomiting and cramping decreased from week 1 
to week 5 (22% to 5%) as did the risk of pregnancy loss in the presence of nausea and/or 
vomiting, cramping, and bleeding (71% to 6%).  
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Regression modeling results 
Results for individual time-varying covariates in time-varying effect regression models are 
presented in Table 4.4. Any versus no bleeding was associated with pregnancy loss in week 1 
(hazard ratio (HR) 6.21, 95% CI: 3.79, 10.18) and week 2 (HR 2.31, 95% CI: 1.23, 4.31), but not 
in weeks 3-5. Thus, the hazard ratio for week 1 was significantly different from the hazard ratio 
for week 5 (HR 1.49, 95% CI 0.80, 2.77). Similar results were observed for light/moderate/heavy 
bleeding versus none/spotting (week 1 HR 8.67, 95% CI: 4.70, 16.01; week 2 HR 3.00, 95% CI: 
1.41, 6.37; week 3 HR 1.42, 95% CI 0.52, 3.84) and moderate/heavy bleeding versus 
none/spotting/light bleeding (week 1 HR 8.27, 95% CI: 4.18, 16.36; week 2 HR 4.65, 95% CI: 
2.02, 10.71; week 4 HR 0.85, 95% CI 0.22, 3.24), with hazard ratios in week 1 being 
significantly different from hazard ratios in week 3 or week 4. Any nausea and/or vomiting were 
not associated with pregnancy loss in week 1; however, it was inversely associated with loss in 
weeks 2-5 (HR range 0.63 to 0.31, all 95% CI below 1.00). Similar results were observed for 
nausea only versus no nausea and/or vomiting (HR range 0.52 to 0.36, all 95% CI below 1.00). 
Any vomiting versus no nausea and/or vomiting was inversely associated with loss in weeks 3-5, 
though the estimate for week 4 was not significant (week 3 HR 0.28, 95% CI: 0.09, 0.83; week 4 
HR 0.11, 95% CI: 0.00, 10.78; week 5 HR 0.21, 95% CI: 0.07, 0.68). Any versus no cramping 
was associated with pregnancy loss in the first week post positive pregnancy test (HR: 1.80, 95% 
CI: 1.22, 2.65); however, cramping was inversely associated with loss in weeks 3-5, though the 
week 4 effect was not significant (week 3 HR 0.48, 95% CI: 0.26, 0.89; week 4 HR 0.60, 95% 




Results for combinations of time-varying covariates in time-varying effect models are presented 
in Table 4.5. In the first week post positive pregnancy test, women with all three symptoms had 
higher rates of pregnancy loss (HR: 5.19, 95% CI: 2.56, 10.51) compared with women without 
any symptoms, while nausea and/or vomiting and cramping either alone or in combination with 
one another were not associated with loss. In weeks 2-5, nausea and/or vomiting either alone or 




In this preconception cohort, there was weekly variability in the prevalence of signs and 
symptoms in early pregnancy. In particular, the first week following a positive pregnancy test 
when approximately one-third of losses occurred was different from subsequent weeks and the 
variability appeared to be most marked for the more severe signs and symptoms. Specifically, 
moderate/heavy bleeding prevalence declined from 10% in the first week post positive 
pregnancy test to 1% in the fifth week, while prevalence of vomiting increased from 19% in the 
first week to 32% in the fifth week. The relationships between signs and symptoms and 
pregnancy loss also varied across weeks. The positive relationship between bleeding and 
pregnancy loss was most pronounced, and a positive relationship between lower abdominal 
cramping and pregnancy loss was observed, in the first week following a positive pregnancy test. 
Even in the setting of nausea and/or vomiting, bleeding with cramping was associated with 
increased risk of pregnancy loss in the first week. Conversely, nausea and/or vomiting were not 
associated with pregnancy loss in the first week following a positive pregnancy test but were 
inversely associated with loss in subsequent weeks. The presence of all three symptoms was 
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associated with loss in the first week but not in later weeks. This may reflect a particular 
symptomatic presentation of losses in the first week that is different from that occurring slightly 
later in pregnancy. 
 
Previous studies,38 including results presented in Chapter 3, using fixed effect modeling in 
preconception studies with daily follow-up showed that vaginal bleeding was more common in 
pregnancies ending in a loss than in those not ending in a loss. A prior pregnancy cohort study 
calculated week-specific probabilities of loss by bleeding status and showed the greatest 
probability of miscarriage occurred in the earliest weeks in pregnancies with heavy, but not light, 
bleeding.37 A case series on threatened abortion in pregnancies with demonstrated fetal cardiac 
activity showed the prevalence of miscarriage was three times greater in weeks 5-6 than in weeks 
7-20.88 In this study, I found that vaginal bleeding was associated with pregnancy loss but only in 
the first two weeks post positive pregnancy test (at approximately 4-5 weeks gestation), which 
was consistent with the descriptive data from the pregnancy cohort37 and case series.88  
 
As reported in Chapter 3, no significant association between lower abdominal cramping and 
pregnancy loss was observed. However, fixed effect analyses of combinations of signs and 
symptoms co-occurring with cramping, showed that cramping with bleeding was associated with 
pregnancy loss, while cramping with vomiting was inversely associated with pregnancy loss. In 
contrast, using time-varying effects in this study, I found that lower abdominal cramping was 
positively associated with loss in the first week post positive pregnancy test and inversely 
associated with loss in later weeks. When considering combinations of signs and symptoms, I 
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corroborated findings from Chapter 3 that cramping with nausea and/or vomiting was inversely 
associated with loss, but only after the first week post positive pregnancy test. I also found that 
cramping with bleeding and nausea and/or vomiting was associated with loss in the first week 
but not in subsequent weeks. 
 
As reported in Chapter 3, any vomiting during the early pregnancy period was inversely 
associated with pregnancy loss, while only experiencing nausea throughout the early pregnancy 
period was not associated with loss in fixed effect models. However, a previous preconception 
study with monthly reporting of nausea found that nausea was inversely associated with 
pregnancy loss, though nausea in that study was not distinguished from nausea with vomiting.49 
Using time-varying effects in this Chapter, I found that vomiting was inversely associated with 
loss after the first and second weeks post positive pregnancy test, which corroborated the 
findings from fixed effects models in prior studies. However, I found experiencing nausea only 
during a given week was also inversely associated with pregnancy loss after the first week, 
which was in contrast to findings from fixed effects models in Chapter 3. Of note, in the time-
varying effects analysis of this Chapter, women could report nausea only in one week but then 
report vomiting in another week whereas in the fixed covariate, fixed effect models if a woman 
reported vomiting at any time during the five week early pregnancy period, she would have been 
categorized in the vomiting group (applicable to about half of women with nausea). Thus, the 
totality of the exposure (e.g., nausea only) over the first few weeks of early pregnancy was more 
informative for pregnancy loss than individual weeks of exposure as weekly information does 
not capture precedent or subsequent exposures (e.g., vomiting).  
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This study had several strengths. Firstly, the preconception design facilitated the prospective 
capture of signs and symptoms relative to pregnancy loss ascertainment. This minimized the 
potential recall bias that could arise if signs and symptoms were elicited after the loss (i.e., 
exposure misclassification differential by outcome). Secondly, by capturing signs and symptoms 
daily, I was able to evaluate these factors as time-varying covariates with time-varying effects on 
pregnancy loss. Thirdly, by ascertaining pregnancies using sensitive home pregnancy tests, 
pregnancies and pregnancy losses were captured early in gestation. This extended the 
relationship between signs and symptoms and pregnancy loss to very early pregnancy and thus 
increased the applicability of the results to contemporary cohorts of pregnant women who have 
information from early pregnancy testing.4,14 It also facilitated the evaluation the time-varying 
relationships between signs and symptoms of pregnancy loss during the period prior to clinical 
care entry. 
 
Despite these strengths, these findings must be interpreted in light of the study’s limitations. 
Firstly, by study design daily information on signs and symptoms were collected only through 
the first five weeks following a positive pregnancy test; therefore, I was unable to evaluate the 
weekly time-varying effects of signs and symptoms on loss beyond that period. As this 
corresponds with the end of organogenesis and the beginning of the fetal period, signs and 
symptoms in relation to loss may differ from the early pregnancy period. Secondly, despite being 
the largest prospective preconception study with daily follow-up to date,82 there were few 
pregnancy losses beyond the first trimester. Thirdly, I was unable to examine all possible 
combinations of signs and symptoms owing to reduced statistical power. Finally, 7% of 
pregnancies were lost to follow-up <20 weeks gestation, though I used a survival analytic 
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The relationships between signs and symptoms and pregnancy loss were dynamic across early 
pregnancy in this preconception cohort study. In the first week following a positive pregnancy 
test, bleeding and cramping were associated with loss even in the setting of nausea and/or 
vomiting. However, new relationships between signs and symptoms emerged after the second 
week and appeared relatively stable, with nausea and/or vomiting inversely associated and 
bleeding no longer associated with pregnancy loss. Symptomatic presentation of pregnancy loss 
varied by week, and this has clinical implications if corroborated in future preconception studies. 
Specifically, vaginal bleeding after approximately 6 weeks gestation may not necessitate an 
immediate evaluation. While these results suggest that vaginal bleeding before 6 weeks is 
associated with a higher rate of pregnancy loss and that nausea and/or vomiting are indicative of 
a positive response to pregnancy, the maternal physiologic responses to early pregnancy, causes 
of signs and symptoms and their relation to early pregnancy loss require more basic science, 
clinical, and epidemiologic research. Developing prognostic models for pregnancy loss inclusive 
of time-varying signs and symptoms will be useful for women and clinicians in terms of 





Table 4.1. Prevalence of signs and symptoms by week following positive pregnancy test, 
overall and by pregnancy loss status 
 Overall , % 
(n=335) 




No symptoms    
  Week 1 13 13 12 
  Week 2 18 15 27 
  Week 3 14 13 20 
  Week 4 11 8 24 
  Week 5 13 12 25 
Any bleeding    
  Week 1 20 13 39 
  Week 2 16 14 24 
  Week 3 18 17 24 
  Week 4 19 18 29 
  Week 5 22 22 25 
Light/moderate/heavy  bleeding    
  Week 1 13 7 29 
  Week 2 10 8 18 
  Week 3 8 8 11 
  Week 4 11 10 15 
  Week 5 10 10 9 
Moderate/heavy bleeding    
  Week 1 10 6 23 
  Week 2 7 5 17 
  Week 3 4 4 5 
  Week 4 6 7 6 






Table 4.1. Prevalence of signs and symptoms by week following positive pregnancy test, 
overall and by pregnancy loss status (cont.) 
 Overall , % 
(n=335) 




Any nausea and/or vomiting    
  Week 1 75 72 81 
  Week 2 64 66 55 
  Week 3 78 81 62 
  Week 4 81 86 54 
  Week 5 81 83 58 
Any vomiting    
  Week 1 19 17 24 
  Week 2 14 14 18 
  Week 3 19 21 9 
  Week 4 22 25 6 
  Week 5 32 34 17 
Nausea only a    
  Week 1 74 72 80 
  Week 2 58 62 42 
  Week 3 72 75 55 
  Week 4 72 76 49 
  Week 5 67 70 50 
Any cramping    
  Week 1 72 69 77 
  Week 2 56 57 52 
  Week 3 48 51 29 
  Week 4 50 52 40 
  Week 5 53 56 33 
 
a Nausea, but not vomiting, during the week   
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Table 4.2. Cumulative probabilities of pregnancy loss by occurrence of signs and 
symptoms each week following positive pregnancy test 
 Presence Absence 
 Probability of loss  
(95% confidence interval) 
Probability of loss  
(95% confidence interval) 
Any bleeding   
  Week 1 0.64 (0.48, 0.79) 0.20 (0.16, 0.25) 
  Week 2 0.31 (0.16, 0.46) 0.16 (0.12, 0.21) 
  Week 3 0.22 (0.10, 0.33) 0.14 (0.10, 0.18) 
  Week 4 0.23 (0.11, 0.34) 0.12 (0.08, 0.17) 
  Week 5 0.13 (0.04, 0.22) 0.11 (0.07, 0.15) 
Light/moderate/heavy  bleeding   
  Week 1 0.78 (0.59, 0.96) 0.22 (0.17, 0.27) 
  Week 2 0.40 (0.18, 0.62) 0.17 (0.12, 0.21) 
  Week 3 0.22 (0.03, 0.41) 0.15 (0.11, 0.19) 
  Week 4 0.21 (0.05, 0.37) 0.14 (0.10, 0.18) 
  Week 5 0.11 (0.00, 0.23) 0.11 (0.08, 0.15) 
Moderate/heavy bleeding   
  Week 1 0.76 (0.55, 0.98) 0.23 (0.18, 0.28) 
  Week 2 0.56 (0.27, 0.85) 0.16 (0.12, 0.21) 
  Week 3 0.22 (0.00, 0.53) 0.15 (0.11, 0.19) 
  Week 4 0.14 (0.00, 0.32) 0.14 (0.10, 0.18) 
  Week 5 0.39 (0.00, 0.70) 0.11 (0.07, 0.15) 
Any nausea and/or vomiting   
  Week 1 0.31 (0.24, 0.38) 0.20 (0.10, 0.30) 
  Week 2 0.16 (0.11, 0.21) 0.23 (0.15, 0.30) 
  Week 3 0.12 (0.08, 0.16) 0.27 (0.16, 0.37) 
  Week 4 0.10 (0.06, 0.14) 0.33 (0.22, 0.45) 
  Week 5 0.08 (0.05, 0.12) 0.23 (0.12, 0.35) 
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Table 4.2. Cumulative probabilities of pregnancy loss by occurrence of signs and 
symptoms each week following positive pregnancy test (cont.) 
 Presence Absence 
 Probability of loss  
(95% confidence interval) 
Probability of loss  
(95% confidence interval) 
Any vomiting    
  Week 1 0.39 (0.19, 0.58) 0.20 (0.10, 0.30) 
  Week 2 0.25 (0.10, 0.40) 0.23 (0.15, 0.30) 
  Week 3 0.08 (0.00, 0.15) 0.27 (0.16, 0.37) 
  Week 4 0.04 (0.00, 0.11) 0.33 (0.22, 0.45) 
  Week 5 0.06 (0.00, 0.12) 0.23 (0.12, 0.35) 
Any nausea a    
  Week 1 0.29 (0.21, 0.37) 0.20 (0.10, 0.30) 
  Week 2 0.14 (0.08, 0.19) 0.23 (0.15, 0.30) 
  Week 3 0.13 (0.08, 0.18) 0.27 (0.16, 0.37) 
  Week 4 0.12 (0.07, 0.16) 0.33 (0.22, 0.45) 
  Week 5 0.10 (0.04, 0.15) 0.23 (0.12, 0.35) 
Any cramping   
  Week 1 0.31 (0.24, 0.38) 0.21 (0.11, 0.30) 
  Week 2 0.17 (0.11, 0.23) 0.20 (0.13, 0.26) 
  Week 3 0.09 (0.05, 0.14) 0.20 (0.14, 0.26) 
  Week 4 0.12 (0.06, 0.17) 0.17 (0.11, 0.23) 
  Week 5 0.07 (0.03, 0.12) 0.16 (0.10, 0.22) 
 




Table 4.3. Cumulative probabilities of pregnancy loss by occurrence of combinations of 
signs and symptoms each week following positive pregnancy test  
 Probability of loss  
(95% confidence interval) 
No symptoms a  
  Week 1 0.24 (0.09, 0.38) 
  Week 2 0.26 (0.16, 0.37) 
  Week 3 0.22 (0.10, 0.33) 
  Week 4 0.30 (0.16, 0.45) 
  Week 5 0.20 (0.07, 0.33) 
Cramping only   
  Week 1 0.15 (0.02, 0.32) 
  Week 2 0.15 (0.05, 0.26) 
  Week 3 0.15 (0.00, 0.32) 
  Week 4 0.16 (0.00, 0.36) 
  Week 5 0.25 (0.00, 0.53) 
Nausea/vomiting only   
  Week 1 0.18 (0.03, 0.33) 
  Week 2 0.13 (0.05, 0.21) 
  Week 3 0.17 (0.10, 0.24) 
  Week 4 0.10 (0.04, 0.16) 
  Week 5 0.11 (0.03, 0.18) 
Nausea/vomiting + cramping   
  Week 1 0.22 (0.14, 0.29) 
  Week 2 0.13 (0.06, 0.20) 
  Week 3 0.07 (0.02, 0.13) 
  Week 4 0.08 (0.02, 0.14) 






Table 4.3. Cumulative probabilities of pregnancy loss by occurrence of combinations of 
signs and symptoms each week following positive pregnancy test (cont.) 
 Probability of loss  
(95% confidence interval) 
Nausea/vomiting + cramping + bleeding   
  Week 1 0.71 (0.54, 0.88) 
  Week 2 0.31 (0.14, 0.49) 
  Week 3 0.11 (0.00, 0.22) 
  Week 4 0.14 (0.02, 0.25) 
  Week 5 0.06 (0.00, 0.14) 
 




Table 4.4. Time-varying effects of individual signs and symptoms on pregnancy loss by 
week following positive pregnancy test 
Sign or Symptom Hazard Ratio 95% Confidence Interval 
Any versus no bleeding   
Week 1 6.21  3.79, 10.18 
Week 2 2.31  1.23, 4.31 
Week 3 1.49  0.80, 2.77 
Week 4 1.57  0.88, 2.79 
Week 5 0.84  0.41, 1.73 
Light/moderate/heavy bleeding versus 
none/spotting 
  
Week 1 8.67  4.70, 16.01 
Week 2 3.00  1.41, 6.37 
Week 3 1.42  0.52, 3.84 
Week 4 1.38  0.59, 3.24 
Week 5 0.63  0.18, 2.20 
Moderate/heavy bleeding versus 
none/spotting/light bleeding 
  
Week 1 8.27  4.18, 16.36 
Week 2 4.65  2.02, 10.71 
Week 3 1.36  0.28, 6.52 
Week 4 0.85  0.22, 3.24 
Week 5 2.84  0.71, 11.36 
Any versus no cramping   
Week 1 1.80  1.22, 2.65 
Week 2 0.92  0.58, 1.46 
Week 3 0.48  0.26, 0.89 
Week 4 0.60  0.34, 1.03 





Table 4.4. Time-varying effects of individual signs and symptoms on pregnancy loss by 
week following positive pregnancy test (cont.) 
Sign or Symptom Hazard Ratio 95% Confidence Interval 
Any versus no nausea and/or vomiting   
Week 1 1.33  0.88, 1.99 
Week 2 0.63  0.40, 0.99 
Week 3 0.46  0.30, 0.70 
Week 4 0.37  0.22, 0.60 
Week 5 0.31  0.18, 0.52 
Nausea only a versus no nausea/vomiting   
Week 1 1.21 0.77, 1.91 
Week 2 0.52  0.32, 0.87 
Week 3 0.52  0.33, 0.80 
Week 4 0.44  0.26, 0.73 
Week 5 0.36  0.19, 0.68 
Vomiting versus no nausea/vomiting   
Week 1 1.72  0.82, 3.60 
Week 2 1.03  0.47, 2.24 
Week 3 0.28  0.09, 0.83 
Week 4 0.11  0.00, 10.78 
Week 5 0.21  0.07, 0.68 
 
a Nausea, but not vomiting, during the week   
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Table 4.5. Time-varying effects of combinations of signs and symptoms on pregnancy loss 
by week following positive pregnancy test 
Combination of Signs and 









Week 1     
Cramping only  0.49  0.12, 1.97 0.53  0.13, 2.19 
Nausea/vomiting only 0.62  0.23, 1.72 0.68  0.24, 1.93 
Nausea/vomiting + cramping 0.94  0.56, 1.59 0.87  0.49, 1.54 
Nausea/vomiting + cramping + 
bleeding  
5.19  2.56, 10.51 4.48  2.36, 8.50 
Week 2     
Cramping only  0.55  0.24, 1.25 0.60  0.26, 1.38 
Nausea/vomiting only 0.44  0.22, 0.91 0.50  0.23, 1.07 
Nausea/vomiting + cramping 0.46  0.24, 0.92 0.50  0.25, 1.03 
Nausea/vomiting + cramping + 
bleeding 
1.60  0.67, 3.83 1.35  0.59, 3.07 
Week 3     
Cramping only  0.44  0.12, 1.69 0.58  0.15, 2.19 
Nausea/vomiting only 0.60  0.36, 1.00 0.65  0.38, 1.13 
Nausea/vomiting + cramping 0.24  0.10, 0.56 0.27  0.11, 0.65 
Nausea/vomiting + cramping + 
bleeding  
0.48  0.11, 2.15 0.39  0.11, 1.43 
Week 4     
Cramping only  1.01  0.37, 2.72 0.62  0.14, 2.75 
Nausea/vomiting only 0.35  0.17, 0.70 0.38  0.19, 0.78 
Nausea/vomiting + cramping 0.27  0.12, 0.62 0.28  0.11, 0.70 
Nausea/vomiting + cramping + 
bleeding  





Table 4.5. Time-varying effects of combinations of signs and symptoms on pregnancy loss 
by week following positive pregnancy test (cont.) 
Combination of Signs and 









Week 5     
Cramping only  0.88  0.22, 3.52 0.98  0.24, 4.04 
Nausea/vomiting only 0.41  0.19, 0.88 0.40  0.17, 0.91 
Nausea/vomiting + cramping 0.20  0.07, 0.52 0.19  0.06, 0.61 
Nausea/vomiting + cramping + 
bleeding  
0.01  0.00, 229 0.21  0.05, 0.95 
 
a Reference includes women with no symptoms or with spotting only 
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CHAPTER 5: CONCLUSIONS 
 
SUMMARY OF SPECIFIC AIMS 
 
 
I addressed three specific aims in this dissertation in order to more completely describe the 
natural history of pregnancy loss. First, I systematically reviewed the existing literature on the 
associations between signs and symptoms of pregnancy and subsequent pregnancy loss. Second, 
I used a population-based preconception cohort in the USA with daily prospective ascertainment 
of signs and symptoms from two to seven weeks post-conception to assess the relationships 
between multiple signs and symptoms during early pregnancy and subsequent pregnancy loss in 
the first 20 weeks gestation using a fixed covariate and fixed effect survival analytic approach. 
Third, I used the same preconception cohort and information on signs and symptoms but 
employed a time-varying covariate and time-varying effect survival analytic approach to 
determine if the relationships between multiple signs and symptoms during early pregnancy and 
subsequent pregnancy loss were constant across gestational age. 
 
SUMMARY OF FINDINGS 
 
 
During my systematic review of the literature, I identified two preconception and 16 pregnancy 
cohort studies that attempted to ascertain signs and symptoms prior to pregnancy loss. These 
studies were conducted in several different countries from the 1950s until the 2010s; however, 
most studies, including the two preconception studies, only examined relationships between 
individual signs and symptoms and pregnancy loss. Two pregnancy cohort studies examined the 
relationships between multiple signs and symptoms and pregnancy loss, but they date from the 
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1950s when pregnancy recognition occurred much later in gestation than currently. A more 
recent study examined nausea in the setting of vaginal bleeding but only among women 
presenting with threatened abortion. From this systematic review, some relationships between 
signs and symptoms and pregnancy loss were fairly consistent: vaginal bleeding, particularly 
heavier bleeding, was associated with increased risk of loss, while vomiting, and in some studies 
nausea also, was inversely associated with pregnancy loss even in the setting of vaginal bleeding. 
However, notable data gaps were identified. First, since many of the existing studies were 
pregnancy cohorts, the earliest pregnancy losses, which constituted the majority of losses, were 
not included. Second, the relationships between multiple signs and symptoms and pregnancy loss 
were limited and evaluations of temporal ordering of signs and symptoms and pregnancy loss 
were absent. Third, only one pregnancy cohort study evaluated time-varying probabilities of 
pregnancy loss by timing of vaginal bleeding. These data gaps served as the impetus for the 
second and third aims of this dissertation. 
 
In the second aim, I described the cumulative incidence of several individual signs and 
symptoms, as well as combinations and temporal patterning of signs and symptoms, (namely 
vaginal bleeding, lower abdominal cramping, nausea, and vomiting) during the earliest period of 
pregnancy from two to seven weeks post-conception in a preconception cohort. I then described 
the cumulative incidence of pregnancy loss by the presence of individual, combinations, and 
patterns of signs and symptoms during early pregnancy. Finally, using a fixed covariate and 
fixed effect survival modeling approach, I estimated the associations between individual, 
combinations, and patterns of signs and symptoms and pregnancy loss <20 weeks gestation. I 
found that lower abdominal cramping was common in early pregnancy, though it was not 
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associated with pregnancy loss absent other signs and symptoms. Vomiting and nausea were also 
common in early pregnancy. The experience of vomiting, but not nausea alone, was associated 
with a lower incidence of loss. While vaginal bleeding was less common in early pregnancy, it 
was associated with increased incidence of loss, particularly if accompanied by lower abdominal 
cramping, though if vomiting subsequently followed bleeding the incidence of loss was lower 
than if vomiting remained absent. 
 
In the third aim, I evaluated the weekly associations between individual and combinations of 
signs and symptoms and pregnancy loss in the first five weeks after a positive home pregnancy 
test, approximately two to seven weeks post-conception, using weekly time-varying covariates 
and time-varying effects in a survival analytic model. I found that the weekly prevalence of signs 
and symptoms was fairly stable for most signs and symptoms though more variation was noted 
for the more severe symptoms (e.g., vomiting and moderate/heavy vaginal bleeding); however, 
the relationships between signs and symptoms and pregnancy loss varied across early pregnancy. 
The first week after pregnancy discovery appeared to be particularly vulnerable to pregnancy 
loss in the setting of vaginal bleeding and lower abdominal cramping, even if nausea and/or 
vomiting were present; however, in the second through fifth weeks, bleeding accompanied by 
cramping, nausea and/or vomiting was no longer associated with loss. In contrast, nausea and/or 
vomiting, alone or in combination with lower abdominal cramping, were inversely associated 
with loss in the second through fifth weeks, but not in the first week.  
 
There were many strengths underlying this work. The first was the use of information from a 
preconception cohort with prospective daily follow-up of women from the beginning of their 
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pregnancy attempt. Second, the use of sensitive urine-based home pregnancy tests facilitated the 
capture of the earliest pregnancies and pregnancy losses occurring prior to presentation for 
clinical care. Since very early losses comprise the majority of pregnancy loss, this increased the 
direct applicability of my findings to early pregnancy losses, particularly those in the first 
trimester. Third, the daily capture of signs and symptoms from two to seven weeks post-
conception minimized the possibility for recall bias in the reporting of signs and symptoms, and 
potential bias in the observed associations between signs and symptoms and pregnancy loss. The 
daily capture of information also facilitated the evaluation of patterns and temporal ordering of 
signs and symptoms, in relation to pregnancy loss, which was another novel contribution to the 
literature. Finally, the daily capture of information on signs and symptoms allowed for the use of 
time-varying covariates and the estimation of time-varying effect, which revealed that the 
relationships between signs and symptoms and pregnancy loss changed during early pregnancy, 
another novel finding. 
 
There were also some limitations to this work. First, despite being the largest preconception 
study with daily follow-up, there were few pregnancy losses after 14 weeks gestation, limiting 
the amount of information and applicability of findings to losses in the second trimester. Second, 
by design, data on signs and symptoms were collected daily only from two to seven weeks post-
conception. Therefore, the weekly time-varying effects of signs and symptoms on loss could 
only be estimated for this time period, which corresponds to the embryonic period. Finally, there 
was a small (7%) loss to follow-up in the study before 20 weeks gestation. However, survival 
analytic censoring approaches were used to estimate effects with appropriate precision despite 




In light of these strengths and limitations, I will comment on the internal and external validity of 
this work. I believe that the analytic aims are internally valid; they are not hindered by 
information bias, selection bias, or confounding. While women were prompted daily as to the 
presence or absence of multiple signs and symptoms, I have no reason to believe that women 
would respond to these prompts differently by their eventual loss status. Indeed, the prospective 
ascertainment of signs and symptoms relative to loss ascertainment is a strength of these data 
that mitigates information bias (e.g., measurement error). While there was some loss to follow-
up, all available data was included in the analysis using survival analytic techniques; this 
mitigates selection bias due to loss to follow-up. While this descriptive work was designed to be 
inclusive of a broad range of couples achieving pregnancy, and thus, no a priori plan was 
established to examine signs and symptoms of pregnancy loss within subgroups of women (e.g., 
by parity or maternal age), I did examine several maternal characteristics as possible 
confounding variables of the association between signs and symptoms and loss. None of these 
characteristics met statistical criteria for inclusion as confounding variables in the statistical 
models, and the existing literature does not firmly support the inclusion of any of these variables 
as a priori confounding variables in the models. Therefore, I do not believe that confounding has 
affected this study. 
 
With regards to the external validity, or generalizability, of these findings, I believe these 
findings apply to pregnancies achieved spontaneously (e.g., without the use of assisted 
reproductive technologies). The LIFE Study was designed to be inclusive of a broad range of 
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couples attempting pregnancy; therefore, exclusion criteria were minimal. The LIFE Study was 
also population-based to be generalizable to the population of couples attempting pregnancy. 
While the LIFE Study, as with all studies in the US relying upon volunteers, had a study 
population that was better educated, had higher income, and was less racially/ethnically diverse 
than the US population, I do not believe that differences in income, education, or race/ethnicity 
would impact the relationship between signs and symptoms and pregnancy loss. It is possible 
that unprompted reporting of signs and symptoms may differ by these characteristics; however, 
women were prompted daily on their signs and symptoms. From the perspective of putative 
biological mechanisms, there is no evidence to suggest that the underlying relationships between 
signs and symptoms and pregnancy loss would differ by these characteristics. I would not extend 
these findings to women with pregnancies achieved through assisted reproductive technologies 
because these women receive exogenous hormones prior to and during pregnancy. As various 
maternal hormones are believed to be associated with the presence of multiple signs and 
symptoms, it may be that the relationship between signs and symptoms and pregnancy loss are 
different among women receiving exogenous hormones than among women not receiving these 
hormones (e.g., spontaneously achieved pregnancies).       
 
SIGNIFICANCE OF FINDINGS 
 
 
In this dissertation, I have described some novel relationships between signs and symptoms and 
pregnancy loss. The absence of signs and symptoms was not associated with an appreciable 
difference in pregnancy loss incidence. However, the presence of individual signs and symptoms 
and combinations of signs and symptoms was associated with an increased or decreased 
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incidence of pregnancy loss. The absence of signs and symptoms was not as informative for 
pregnancy loss risk as the presence of one or more specific symptoms or signs. Furthermore, this 
work demonstrated that the time period over which signs and symptoms did or did not occur was 
an important consideration for estimating pregnancy loss incidence.  
 
The novel findings from the two distinct, but complimentary, analytic approaches have 
implications for the epidemiologic, clinical, and basic science communities as they suggested 
that the inference of findings from a fixed effect model using a fixed covariate covering a wide 
exposure window (e.g., effect of bleeding in early pregnancy on pregnancy loss) may be 
different from the inference of findings from a time-varying effect model using time-varying 
covariates over shorter intervals of exposure (e.g., effect of bleeding immediately following a 
positive pregnancy test versus bleeding several weeks after a positive pregnancy test on 
pregnancy loss). While time-varying effect modeling may be preferred for assessing sensitive 
windows of exposure relevant for organogenesis (e.g., differences in effects by gestational week 
of exposure), it requires a larger number of subjects than fixed effect modeling. Furthermore, one 
may have data limited by uncertain gestational dating or queries on coarse exposure windows 
necessitating the use of a fixed effect model that will provide an average effect of the exposure 
on the outcome. In some instances, fixed covariates may be preferred to time-varying covariates 
as they provide a summary measure of exposure over a longer period that cannot be captured 
with time-varying covariates. One approach is not necessarily better than the other as they 
answer different questions; consequently, they also have different implications for public health 
messaging. Thus, one must be careful with the interpretation of the results. The findings from the 
104 
 
two analytic aims highlighted these considerations; the significance for each of the three signs 
and symptoms are described below.    
 
Lower abdominal cramping has received limited attention in previous work and has only been 
evaluated in the context of vaginal bleeding. I found that lower abdominal cramping was 
common in early pregnancy and occurred by itself and in combination with nausea and/or 
vomiting and vaginal bleeding. In the absence of other signs or symptoms, lower abdominal 
cramping was not associated with pregnancy loss. However, when cramping was associated with 
vaginal bleeding, the cumulative incidence of loss was higher than for any other combination of 
signs and symptoms in the early pregnancy period. When examining the weekly time-varying 
effects of signs and symptoms, cramping with vaginal bleeding, even in the presence of nausea 
and/or vomiting, was associated with increased risk of pregnancy loss, though only in the first 
week after pregnancy discovery. In contrast, cramping co-occurring with vomiting was 
associated with the lowest cumulative incidence of loss of all combinations of signs and 
symptoms. In weekly time-varying effects analyses, cramping with nausea and/or vomiting was 
associated with decreased risk of loss, though only after the first week post pregnancy discovery. 
Together, these findings suggested that lower abdominal cramping may be the norm rather than 
the exception in early pregnancy. Furthermore, cramping alone was not a harbinger of loss and 
more information on other signs and symptoms is needed to better understand the risk of loss in 
pregnancies where cramping is present. 
 
Vaginal bleeding, particularly more severe bleeding, was associated with an increased risk of 
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pregnancy loss; however, vaginal bleeding often co-occurred with one or more other signs or 
symptoms, which provided greater information on the risk of loss. In women with vaginal 
bleeding and lower abdominal cramping, the subsequent occurrence of vomiting resulted in a 
lower cumulative incidence of pregnancy loss when compared with pregnancy loss among 
women in whom vomiting did not occur. In weekly time-varying effects models, bleeding most 
often occurred with cramping and nausea and/or vomiting. In these models, the presence of all 
three symptoms was associated with an increased risk of loss only during the first week post 
pregnancy discovery. These findings suggested that the presence of vaginal bleeding was most 
likely to be associated with pregnancy loss soon after pregnancy discovery and that the co-
occurrence of nausea and/or vomiting reduced the risk of loss in the setting of vaginal bleeding 
only somewhat later in gestation after the period of the greatest loss incidence had passed.     
 
By evaluating nausea and/or vomiting as both fixed effects and time-varying effects, I found two 
different but complimentary associations with pregnancy loss that provided more insight into the 
relationship of nausea and vomiting and loss during early pregnancy. Under the fixed covariate 
and fixed effect modeling, I found that vomiting, but not nausea alone, was associated with a 
lower cumulative incidence of pregnancy loss. However, in the weekly time-varying covariate 
and time-varying effect models, I found that after the first week post pregnancy discovery both 
vomiting, and nausea alone were associated with decreased risks of pregnancy loss. This may be 
due to the different exposure definitions used in the two models. In the fixed effect models, a 
woman may have had nausea alone for several weeks. However, if she had just one day of 
vomiting at any point during the early pregnancy period, she would have been classified as 
having vomiting for the entire period. In the time-varying covariate models, however, a woman 
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may have had several weeks of nausea only and then had a single week with vomiting. Her 
weeks of nausea alone would have been evaluated as nausea alone and her later week of 
vomiting would have counted as vomiting for the single week. Together, these findings 
suggested that the totality of the exposure (e.g., nausea only without any vomiting) during the 
early pregnancy period may have been more informative for pregnancy loss than individual 
weeks of exposure. 
 
This work points to areas for further exploration in epidemiologic, clinical, and basic science 
research. First, the prompt for lower abdominal cramping in this study, ‘lower belly cramping,’ 
may capture a heterogeneous symptom with possibly heterogeneous causes. For example, 
cramping consistent with menstrual-like cramps may reflect uterine contraction early in gestation 
associated with expulsion of the products of conception. Alternatively, later in gestation, less 
severe lower abdominal cramping of a different character may result from rising estrogen levels 
that are associated both with a healthy ongoing pregnancy and uterine contractility. Future work 
in epidemiologic studies should seek to better document and grade the severity and typology of 
lower abdominal cramping in order to better understand its relation to pregnancy loss. Clinical 
and basic science studies may focus on more directly observing uterine contractility during early 
pregnancy via ultrasound or other measures to better capture the physiologic response of the 
uterus to implantation and subsequent embryonic growth or demise. Second, the findings from 
time-varying effect models of vaginal bleeding and pregnancy loss provide evidence that the 
symptomatology of pregnancy loss may differ by gestational age and that these differences occur 
quite early in gestation, as soon as the first week after pregnancy discovery or roughly two weeks 
post-conception. This may be particularly important information for women and clinicians trying 
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to identify an impending pregnancy loss. It may also be important for epidemiologic researchers 
designing measures in preconception and pregnancy studies as using one global variable to 
assess a sign or symptom over an entire trimester may result in missing important associations 
within smaller time intervals. Third, the findings on nausea and vomiting in relation to loss 
highlighted that the evaluation of an exposure over a longer time period may provide different 
inferences than the evaluation of an exposure over shorter time intervals in relation to an 
outcome. As our understanding of the causes of embryonic development and demise is still in its 
infancy, we should continue to explore a wide range of exposure periods in our analyses but 
collect data in smaller time intervals since we can collapse smaller intervals into larger ones but 





The findings of this dissertation suggest that developing prognostic models for pregnancy loss by 
incorporating multiple time-varying signs and symptoms may be useful for women and clinicians 
to address the questions regarding the risk of an early pregnancy loss. However, future studies 
utilizing prospectively collected daily data are needed to corroborate these findings and extend 
our understanding of signs and symptoms and pregnancy loss at the population level. More work 
also is needed to understand signs and symptoms in relation both to maternal characteristics, 
such as hormonal profiles and demographic and lifestyle characteristics, and fetal characteristics, 




Specifically, future studies should evaluate whether the natural history of pregnancy loss 
observed in this population-based cohort of spontaneously achieved pregnancies is replicated in 
other populations of spontaneous achieved pregnancies and pregnancies achieved through 
assisted reproductive technologies. Given the expense of conducting preconception cohort 
studies, existing data, such as that collected at the daily level by mobile applications designed to 
track signs and symptoms associated with the menstrual cycle and pregnancy, may be leveraged 
to determine if the findings observed here are replicated among other populations. Furthermore, 
these data sources often collect more signs and symptoms than those queried in this study, for 
example, breast tenderness, smell and taste aversions, fatigue. Thus, future studies could extend 
the work completed in this dissertation on the natural history of pregnancy loss. More signs and 
symptoms could also potentially improve the predictive value of prognostic models if they are 
found to be associated with pregnancy loss. 
 
Pregnancies achieved through assisted reproductive technologies offer unique opportunities to 
examine biomarkers and possible biological mechanisms that underlie the signs and symptoms of 
pregnancy loss. For example, the quality of embryos can be assessed in relation to the 
appearance of signs and symptoms and their relationships with pregnancy loss. Furthermore, 
since women with pregnancies achieved through assisted reproductive technologies are closely 
observed at multiple clinic visits during early pregnancy and are known to be highly compliant 
with their medical care, quantitative values of serum and urinary hCG, as well as serum and 
urinary levels of progesterone, estrogen, and their metabolites, over the course of early 
pregnancy can be assessed in relation to the appearance of signs and symptoms and their 
relationships with pregnancy loss. These studies could support or refute the theories that high 
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progesterone and hCG levels are associated with vomiting while high estrogen levels are 
associated with lower abdominal cramping and provide new insights into the hormonal basis of 
the symptomatology of early pregnancy and pregnancy loss. 
 
Future work is also needed by clinical and basic scientists to increase our understanding of the 
physiologic processes underlying (mal)adaption to pregnancy, in particular, the physiology of 
lower abdominal cramping. Given the time-varying effects of lower abdominal cramping in 
relation to pregnancy loss observed in this study, lower abdominal cramping likely has 
heterogeneous typology and heterogeneous causes. Using ultrasound, uterine contractility can be 
observed and correlated with hormonal profiles and other uterine features (e.g., presence of 
subchorionic hematoma, uterine fibroids) to better understand the relationship between lower 
abdominal cramping and pregnancy loss.  
 
This dissertation work serves as a much-needed foundation for exploring the complex 
relationships among maternal and fetal characteristics (e.g., maternal hormones and embryo 
quality), multiple and varied signs and symptoms of early pregnancy, and pregnancy loss. It 
appears that concerning and reassuring patterns of signs and symptoms of early pregnancy loss 
do exist, yet their biologic mechanisms remain to be fully elucidated. Future work should focus 
on the interplay of hormonal and physiologic adaptions to early pregnancy, symptomatology, and 
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Appendix A: Definition and dating of pregnancy loss 
 
 
Pregnancy loss is identified using the following definition: 
Following a single positive pregnancy test and in the absence of a subsequent live birth, 
1)  Diagnostic test  
2)  Saw a doctor for loss  
3)  Bleeding pattern consistent with expulsion of products of conception  
 
Diagnostic test includes negative pregnancy test, ultrasound indicated fetus died, or heartbeat not 
detected. Saw a doctor for loss is presumably to confirm loss by diagnostic test. Bleeding pattern 
consistent with expulsion of products of conception is ≥2 consecutive days of bleeding where ≥2 
consecutive days are light, moderate, or heavy bleeding) in the absence of a diagnostic 
test/doctor visit consistent with the amount of blood loss expected during the expulsion of 
products of conception.78  
 
For this dissertation, early pregnancy loss was defined as a pregnancy loss (described above) 






The date of pregnancy loss ascertainment using the following method: 
1)  Diagnostic test: Date of diagnostic test confirming loss. 
2)  Saw a doctor for loss: Date of seeing a doctor for loss. 
3)  Bleeding pattern: Date of the midpoint of the bleeding episode consistent with expulsion  
 of products of conception.  
 
The first day of the bleeding episode is the first day of light, moderate, or heavy bleeding and the 
last day of the episode is the last day of any bleeding. The midpoint of the bleeding episode is 
used to avoid bias associated with assigning either the first or the last day of the episode as the 
date of ascertainment of loss.  This approach is commonly used in interval censoring to avoid 
bias.  With other methods of ascertainment, a woman may have a pregnancy loss ascertained at 





Appendix B: Multiple imputation model 
 
The multiple imputation models included the several maternal characteristics to inform the daily 
values for signs and symptoms.  Note that in the multiple imputation models, maternal 
characteristics were imputed first if missing based on other maternal characteristics; thus, the 
imputation for signs and symptoms were based on full information on maternal characteristics. 
Recruitment site, employment status, smoking status, age category, history of gynecologic 
problem, body mass index category, race/ethnicity, education, income, history of pregnancy loss, 







Appendix C: Maternal characteristics by pregnancy outcome 
 
Female Characteristics by Pregnancy Outcome (n=341) 









   n (%) n (%) n (%) n (%) p-value 
Age      
   <25 years old 5 (20) 18 (72) 1 (4) 1 (4) 0.02 
   25-29 years old 42 (27) 87 (55) 17 (11) 12 (8)  
   30-34 years old 29 (25) 79 (69) 3 (3) 3 (3)  
   35+ years old 19 (43) 19 (43) 3 (7) 3 (7)  
Race/Ethnicity      
   Non-Hispanic White 80 (28) 166 (59) 23 (8) 14 (5) 0.47 
   Non-Hispanic Black 3 (50) 2 (50) 0 (0) 0 (0)  
   Hispanic 7 (24) 19 (66) 1 (3) 2 (7)  
   Other 4 (20) 13 (65) 0 (0) 3 (15)  
Education      
   High school or less 6 (40) 9 (60) 0 (0) 0 (0) 0.43 
   Some college or more 88 (27) 192 (60) 23 (7) 19 (6)  
Income      
   <$50,000 11 (25) 29 (66) 3 (7) 1 (2) 0.41 
   $50-99,999 51 (32) 87 (54) 14 (9) 9 (6)  
   $100,000+ 29 (23) 82 (65) 7 (6) 9 (7)  
Employed      
   No 20 (29) 37 (54) 4 (6) 7 (10) 0.26 
   Yes 75 (27) 166 (61) 20 (7) 12 (4)  
Body mass index      
   <18.5 2 (40) 3 (60) 0 (0) 0 (0) 0.54 
   18.5-24.9 41 (25) 101 (62) 15 (9) 7 (4)  
   25.0-29.9 23 (26) 53 (60) 4 (5) 8 (9)  
   30.0+ 29 (35) 45 (54) 5 (6) 4 (5)  
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Female Characteristics by Pregnancy Outcome (cont.) 









 n (%) n (%) n (%) n (%) p-value 
Site      
   Michigan 18 (28) 42 (65) 5 (8) 0 (0) 0.18 
   Texas 77 (28) 161 (58) 19 (7) 19 (7)  
Prior delivery      
   No prior pregnancy 36 (27) 81 (61) 10 (8) 5 (4) 0.43 
   No prior delivery 7 (26) 13 (48) 4 (15) 3 (11)  
   Prior delivery 51 (28) 108 (60) 10 (6) 10 (6)  
Prior loss      
   No prior pregnancy 36 (27) 81 (61) 10 (8) 5 (4) 0.23 
   No prior loss 34 (24) 81 (58) 12 (9) 12 (9)  
   Prior loss 24 (35) 40 (59) 2 (3) 2 (3)  
Smoker at enrollment      
   No 88 (28) 189 (59) 23 (7) 18 (6) 0.94 






















LTF: loss to follow-up  
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Appendix D: Maternal characteristics by method of loss ascertainment 
 



















   n (%) n (%) n (%) n (%) n (%) p-value 
Age       
   <25 years old 0 (0) 0 (0) 2 (40) 0 (0) 3 (60) 0.17 
   25-29 years old 6 (14) 10 (24) 15 (36) 5 (12) 6 (14)  
   30-34 years old 2 (7) 12 (41) 10 (34) 0 (0) 5 (17)  
   35+ years old 3 (16) 8 (42) 5 (26) 1 (6) 2 (11)  
Race/Ethnicity       
   White 11 (14) 23 (29) 28 (35) 5 (6) 13 (16) 0.75 
   Black 0 (0) 1 (33) 1 (33) 1 (33) 0 (0)  
   Hispanic 0 (0) 3 (43) 2 (29) 0 (0) 2 (29)  
   Other 0 (0) 2 (50) 1 (25) 0 (0) 1 (25)  
Education       
   ≤ High school  0 (0) 0 (0) 3 (50) 1 (17) 2 (33) 0.26 
   ≥ Some college  11 (13) 29 (33) 29 (33) 5 (6) 14 (16)  
Income       
   <$50,000 0 (0) 1 (9) 6 (55) 1 (9) 3 (27) 0.15 
   $50-99,999 8 (16) 15 (29) 14 (27) 5 (10) 9 (18)  
   $100,000+ 2 (7) 12 (41) 12 (41) 0 (0) 3 (10)  
Employed       
   No 0 (0) 5 (25) 9 (45) 1 (17) 5 (25) 0.26 
   Yes 11 (15) 25 (33) 23 (31) 5 (83) 7 (15)  
Body mass index       
   <18.5 1 (50) 0 (0) 0 (0) 0 (0) 1 (50) 0.40 
   18.5-24.9 6 (15) 9 (22) 16 (39) 3 (7) 7 (17)  
   25.0-29.9 3 (13) 9 (39) 5 (22) 1 (4) 5 (22)  

























 n (%) n (%) n (%) n (%) n (%) p-value 
Site       
   Michigan 5 (28) 7 (39) 4 (22) 1 (6) 1 (6) 0.09 
   Texas 6 (8) 23 (30) 28 (36)  5 (6) 15 (19)  
Prior delivery       
   No prior 
 
5 (14) 11 (31) 11 (31) 3 (8) 6 (17) 0.98 
   No prior delivery 1 (14) 3 (43) 2 (29) 0 (0) 1 (14)  
   Prior delivery 4 (8) 16 (31) 19 (37) 3 (6) 9 (18)  
Prior loss       
   No prior 
 
5 (14) 11 (31) 11 (31) 3 (8) 6 (17) 0.95 
   No prior loss 4 (12) 10 (29) 13 (38) 2 (6) 5 (15)  
   Prior loss 1 (4) 9 (38) 8 (33) 1 (4) 5 (21)  
Smoker at 
enrollment 
      
   No 10 (91) 29 (97) 28 (88) 6 (100) 15 (94) 0.64 















































Cumulative incidence of positive pregnancy test by cycle day 
Cycle day Cumulative incidence 
24 5% 
24 10% 
27 25% 
29 50% 
32 75% 
37 90% 
44 95% 
 
